COHEN VETERANS BIOSCIENCE INC: Form 990, tax year 2019

View the entire original 990 at ProPublica ↗

Organization
COHEN VETERANS BIOSCIENCE INC (EIN 47-1981973)
Tax period
2019-07-01 to 2020-06-30
Filed
2020-10-26
IRS object ID
202023009349301002
Schema version
2019v5.1
Source
Download XML · Original 990 at ProPublica

Every field in the e-filed return. Faint text is the IRS element name, for citing.

Return header ReturnHeader

FieldValueIRS element (for citing)
Return2020-10-26T09:33:08-05:00ReturnTs
Tax Period End2020-06-30TaxPeriodEndDt

Preparer Firm PreparerFirmGrp

FieldValueIRS element (for citing)
Preparer Firm EIN431985162PreparerFirmEIN

Preparer Firm Name PreparerFirmName

FieldValueIRS element (for citing)
Business Name Line1SMITH SULLIVAN & BROWN PCBusinessNameLine1Txt

Preparer US Address PreparerUSAddress

FieldValueIRS element (for citing)
Address Line180 FLANDERS ROAD - SUITE 200AddressLine1Txt
CityWESTBOROUGHCityNm
State AbbreviationMAStateAbbreviationCd
ZIP01581ZIPCd
FieldValueIRS element (for citing)
Return Type990ReturnTypeCd
Tax Period Begin2019-07-01TaxPeriodBeginDt

Filer Filer

FieldValueIRS element (for citing)
EIN471981973EIN

Business Name BusinessName

FieldValueIRS element (for citing)
Business Name Line1COHEN VETERANS BIOSCIENCE INCBusinessNameLine1Txt
FieldValueIRS element (for citing)
Business Name ControlCOHEBusinessNameControlTxt
Phone6469704325PhoneNum

US Address USAddress

FieldValueIRS element (for citing)
Address Line11 BROADWAY 14TH FLOORAddressLine1Txt
CityCAMBRIDGECityNm
State AbbreviationMAStateAbbreviationCd
ZIP02142ZIPCd

Business Officer BusinessOfficerGrp

FieldValueIRS element (for citing)
PersonMAGALI HAAS MD PHDPersonNm
Person TitleCEO & PRESIDENTPersonTitleTxt
Phone6469704325PhoneNum
Signature2020-10-26SignatureDt
Discuss With Paid PreparerYes (1)DiscussWithPaidPreparerInd

Preparer Person PreparerPersonGrp

FieldValueIRS element (for citing)
Preparer PersonSANDRA M BROWN CPAPreparerPersonNm
PTINP01614103PTIN
Phone5088717178PhoneNum
Preparation2020-10-26PreparationDt

Filing Security Information FilingSecurityInformation

IP Address IPAddress

FieldValueIRS element (for citing)
I Pv4 Address71.248.188.134IPv4AddressTxt
FieldValueIRS element (for citing)
IP2020-10-26IPDt
IP Tm10:31:57IPTm
IP TimezoneEDIPTimezoneCd
Filing License TypePFilingLicenseTypeCd
At Submission Creation Device Id69E9977AC052CEB93F1ED3E2D4B07C277CAC5DE2AtSubmissionCreationDeviceId
At Submission Filing Device Id69E9977AC052CEB93F1ED3E2D4B07C277CAC5DE2AtSubmissionFilingDeviceId
FieldValueIRS element (for citing)
Tax2019TaxYr
Build TS2021-01-29 14:40:06ZBuildTS

Form 990 IRS990

FieldValueIRS element (for citing)
Principal OfficerMAGALI HAAS MD PHDPrincipalOfficerNm

US Address USAddress

FieldValueIRS element (for citing)
Address Line11 BROADWAY 14TH FLOORAddressLine1Txt
CityCAMBRIDGECityNm
State AbbreviationMAStateAbbreviationCd
ZIP02142ZIPCd
FieldValueIRS element (for citing)
Gross Receipts$16,470,665GrossReceiptsAmt
Group Return For Affiliates0GroupReturnForAffiliatesInd
Organization501c3Yes (X)Organization501c3Ind
Website AddressWWW.COHENVETERANSBIOSCIENCE.ORGWebsiteAddressTxt
Type Of Organization CorpYes (X)TypeOfOrganizationCorpInd
Formation2014FormationYr
Legal Domicile StateMALegalDomicileStateCd
Activity Or MissionFAST-TRACKING PRECISION DIAGNOSTICS AND PERSONALIZED THERAPEUTICS FOR ADVANCING BRAIN HEALTHActivityOrMissionDesc
Voting Members Governing Body5VotingMembersGoverningBodyCnt
Voting Members Independent2VotingMembersIndependentCnt
Total Employee35TotalEmployeeCnt
Total Volunteers0TotalVolunteersCnt
Total Gross UBI$0TotalGrossUBIAmt
Net Unrelated Bus Txbl Incm$0NetUnrelatedBusTxblIncmAmt
PY Contributions Grants$20,795,052PYContributionsGrantsAmt
CY Contributions Grants$16,316,026CYContributionsGrantsAmt
PY Program Service Revenue$0PYProgramServiceRevenueAmt
CY Program Service Revenue$0CYProgramServiceRevenueAmt
PY Investment Income$98,872PYInvestmentIncomeAmt
CY Investment Income$154,639CYInvestmentIncomeAmt
PY Other Revenue$145,524PYOtherRevenueAmt
CY Other Revenue$0CYOtherRevenueAmt
PY Total Revenue$21,039,448PYTotalRevenueAmt
CY Total Revenue$16,470,665CYTotalRevenueAmt
PY Grants And Similar Paid$2,786,841PYGrantsAndSimilarPaidAmt
CY Grants And Similar Paid$1,112,861CYGrantsAndSimilarPaidAmt
PY Benefits Paid To Members$0PYBenefitsPaidToMembersAmt
CY Benefits Paid To Members$0CYBenefitsPaidToMembersAmt
PY Salaries Comp Emp Bnft Paid$4,994,068PYSalariesCompEmpBnftPaidAmt
CY Salaries Comp Emp Bnft Paid$7,099,520CYSalariesCompEmpBnftPaidAmt
PY Total Prof Fndrsng Expns$0PYTotalProfFndrsngExpnsAmt
CY Total Prof Fndrsng Expns$0CYTotalProfFndrsngExpnsAmt
CY Total Fundraising Expense$27,526CYTotalFundraisingExpenseAmt
PY Other Expenses$12,390,028PYOtherExpensesAmt
CY Other Expenses$9,950,539CYOtherExpensesAmt
PY Total Expenses$20,170,937PYTotalExpensesAmt
CY Total Expenses$18,162,920CYTotalExpensesAmt
PY Revenues Less Expenses$868,511PYRevenuesLessExpensesAmt
CY Revenues Less Expenses-$1,692,255CYRevenuesLessExpensesAmt
Total Assets BOY$24,190,269TotalAssetsBOYAmt
Total Assets EOY$18,865,456TotalAssetsEOYAmt
Total Liabilities BOY$12,988,921TotalLiabilitiesBOYAmt
Total Liabilities EOY$8,431,760TotalLiabilitiesEOYAmt
Net Assets Or Fund Balances BOY$11,201,348NetAssetsOrFundBalancesBOYAmt
Net Assets Or Fund Balances EOY$10,433,696NetAssetsOrFundBalancesEOYAmt
Info In Schedule O Part IIIYes (X)InfoInScheduleOPartIIIInd
MissionCOHEN VETERANS BIOSCIENCE IS DEDICATED TO FAST-TRACKING THE DEVELOPMENT OF DIAGNOSTIC TESTS AND PERSONALIZED THERAPEUTICS FOR THE MILLIONS OF VETERANS AND CIVILIANS WHO SUFFER THE DEVASTATING EFFECTS OF TRAUMA-RELATED AND OTHER BRAIN DISORDERS.MissionDesc
Significant New Program Srvc0SignificantNewProgramSrvcInd
Significant Change0SignificantChangeInd
Expense$15,387,411ExpenseAmt
Grant$1,112,861GrantAmt
Revenue$0RevenueAmt
DescBRAIN HEALTH PLATFORMSIN ORDER TO FAST-TRACK PRECISION DIAGNOSTICS AND PERSONALIZED THERAPEUTICS AND WELLNESS APPROACHES FOR MAINTENANCE AND RESTORATION OF BRAIN HEALTH, CVB IS LEVERAGING INNOVATION AND TECHNOLOGY TO BUILD PLATFORMS THAT ENABLE DISCOVERY AND DEVELOPMENT ACROSS BRAIN DISEASES. THESE PLATFORMS ALLOW RESEARCHERS FROM ACADEMIA AND INDUSTRY TO ACCESS AND UTILIZE BEST-IN-CLASS TOOLS AND ALLOW EFFORTS TO BE SCALED WITH RIGOR AND REPRODUCIBILITY.(SEE SCHEDULE O FOR FULL DETAIL OF OUR PROGRAMS)PLATFORM EFFORTS FOCUS ON CAPACITY THAT ENABLES RELIABLE DISCOVERY OF BIOMARKERS AND BIOLOGICAL PATHWAYS THAT ARE TRANSLATIONALLY RELEVANT FOR THE DEVELOPMENT OF DIAGNOSTICS AND THERAPEUTIC TARGETS FOR DRUG AND OTHER MEDICAL INTERVENTIONS. EACH PLATFORM IS CREATING RESEARCH TOOLS (E.G. ANIMAL MODELS, DATA STANDARDS, COMPUTATIONAL MODELS, REFERENCE DATABASES, ETC.) THAT WILL ACCELERATE/FOSTER THESE DISCOVERIES. WITHIN THIS FRAMEWORK, CVB HAS ESTABLISHED BOTH INTRAMURAL (RESEARCH CONDUCTED BY, OR INCLUDING, CVB STAFF OR CONTRACTORS) AND EXTRAMURAL RESEARCH PROGRAMS (RESEARCH CONDUCTED VIA GRANTS OR IN COLLABORATION WITH EXTERNAL ACADEMIC, INDUSTRY, FOUNDATION AND GOVERNMENT PARTNERS) AND ALSO OPERATES SEVERAL PUBLIC-PRIVATE PARTNERSHIPS. THESE COOPERATIVE ALLIANCES ORGANIZE AND FUND A NETWORK OF PARTNERS WHO EACH CONTRIBUTE COMPLEMENTARY AND SYNERGISTIC DATA, CAPABILITIES, OR EXPERTISE TO SUPPORT A COMMON ROADMAP FOR IDENTIFYING DIAGNOSTIC BIOMARKERS, BUILDING PREDICTIVE BRAIN DISEASE MODELS, DEVELOPING ROBUST STANDARDIZED TRANSLATIONAL TOOLS, AND CATALYZING PHARMACEUTICAL DRUG DEVELOPMENT. THE EMPHASIS IS ON TEAM SCIENCE WITH COHEN VETERANS BIOSCIENCE SERVING AS ITS HUB.OUR PLATFORM PROGRAMS CURRENTLY INCLUDE THE BRAIN COMMONS (CLOUD-BASED DATA SHARING), EARLYSIGNAL (WEARABLE AND HOME SENSORS FOR MONITORING HEALTH STATUS), RAPID-DX (ESTABLISHING BEST PRACTICES FOR DISCOVERY AND VALIDATION OF BIOMARKERS) AND BRAIN-NET (A CLINICAL TRIAL INFRASTRUCTURE TO EXECUTE TURN-KEY EARLY PHASE CLINICAL STUDIES).BRAIN COMMONS (TRADEMARKED):BUILDING ON PREVIOUS WORK WITH THE OPEN COMMONS CONSORTIUM AND UNIVERSITY OF CHICAGO, CVB HAS CREATED A CLOUD-ACCESSIBLE AND SECURE DIGITAL ECOSYSTEM TO ENABLE AND STIMULATE DATA SHARING AND ANALYSIS IN BOTH PUBLIC AND PRIVATE DOMAINS, FUELING DISCOVERY AND COLLABORATION ACROSS THE MULTIDISCIPLINARY RESEARCH COMMUNITY, AND DRIVING DIAGNOSTIC AND THERAPEUTIC INNOVATION TO REDUCE THE BURDEN OF BRAIN-BASED DISORDERS. LEADING BRAIN-RELATED DISEASE FOUNDATIONS HAVE ACCESS TO THE PLATFORM TO HOUSE THEIR OWN DATA WITHIN THE COMMONS. EARLYSIGNAL (TRADEMARKED): WEARABLE AND SENSOR TECHNOLOGIES HOLD PROMISE IN THE ASSESSMENT AND CONTINUOUS MONITORING OF PATIENTS IN ORDER TO BETTER SCREEN AND DIAGNOSE, MONITOR DISEASE PROGRESSION, AND OBSERVE INTERVENTION RESPONSE OR LACK THEREOF. DIGITAL HEALTH MONITORING ALSO ALLOWS US TO STUDY BRAIN HEALTH AND DISEASE IN UNPRECEDENTED WAYS, BY TRACKING VARIABLES SUCH AS SLEEP, PHYSICAL ACTIVITY, STRESS AND COGNITION, WE MAY BE ABLE TO BETTER UNDERSTAND WHAT CHANGES OVER TIME - AND TO DEVELOP EARLIER AND PREVENTIVE DIAGNOSTICS AND TREATMENTS TO MAKE A DIFFERENCE IN PATIENTS' LIVES. MEDICAL-GRADE DATA IS NEEDED FOR FDA APPROVAL OF SUCH PLATFORMS FOR USE IN MEDICAL DECISION MAKING AND DATA INTEGRATION IS NECESSARY FOR CLINICIANS' WORKFLOW. THIS PROGRAM SUPPORTS MULTIPLE PARTNERS TO TEST AND VALIDATE WEARABLES, SENSORS, APPS AND OTHER DIGITAL HEALTH TECHNOLOGIES FOR USE IN MONITORING BRAIN HEALTH. A CURRENT EXAMPLE OF SUCH WORK IS CVB'S PARTNERSHIP WITH UNIVERSITY OF PENNSYLVANIA, CONDUCTING A STUDY TO TEST AND VALIDATE THE PERFORMANCE OF WEARABLE AND SENSOR DEVICES, USING CVB DESIGNED SECURE AUTOMATED DEIDENTIFIED DATA COLLECTION AND CVB'S STUDY MANAGER TOOL TO SUPPORT CONDUCT OF THE TRIAL.RAPID-DIAGNOSTICS (RAPID-DX (TRADEMARKED)):A BIOMARKER IS A CHARACTERISTIC THAT IS OBJECTIVELY MEASURED AND EVALUATED AS AN INDICATOR OF A NORMAL OR PATHOLOGIC BIOLOGICAL PROCESS OR A RESPONSE TO A THERAPEUTIC INTERVENTION DEVELOPING BIOMARKER-BASED DIAGNOSTICS IS ESSENTIAL TO SHIFTING DIAGNOSIS AND TREATMENT OF PSYCHIATRIC AND NEUROLOGIC CONDITIONS (SUCH AS PTSD AND TBI) FROM A SYNDROMIC OR SYMPTOM-BASED APPROACH TO A BIOLOGICAL, MECHANISTICALLY-BASED ONE THAT TARGETS THE EFFECTS OF TRAUMA AT THEIR MOLECULAR ROOTS. MANY POTENTIAL BRAIN-RELATED BIOMARKERS PUBLISHED IN THE LITERATURE HAVE NOT BEEN INDEPENDENTLY REPLICATED OR ADVANCED THROUGH A QUALIFICATION PROCESS FOR REGULATORY APPROVAL AND USE.RAPID-DX IS A PUBLIC-PRIVATE PARTNERSHIP PROGRAM INCLUDING GOVERNMENT, FOUNDATIONS, AND LEADING ACADEMIC CENTERS ESTABLISHED FOR COLLECTING DATA AND PERFORMING STUDIES NECESSARY TO DISCOVER AND REPLICATE BIOMARKERS AND QUALIFY SUCCESSFUL AND RELEVANT CANDIDATES FOR DEVELOPMENT AS CLINICAL DIAGNOSTICS.THROUGH THIS PROGRAM CVB HAS ESTABLISHED THE CVB BRAIN BIOREPOSITORY IN PARTNERSHIP WITH INDIANA UNIVERSITY. THE GOAL OF THE BIOREPOSITORY IS TO ESTABLISH A CENTRALIZED RESOURCE FOR TISSUE AND BIOSAMPLE STORAGE FOR ENABLING BIOMARKER DISCOVERY, REPLICATION, AND VALIDATION ACROSS A NUMBER OF BRAIN CONDITIONS, INCLUDING POST-TRAUMATIC STRESS DISORDER (PTSD), TRAUMATIC BRAIN INJURY (TBI), SUICIDE, DEMENTIA, MAJOR DEPRESSIVE DISORDER AND OTHER MENTAL HEALTH DISORDERS, AMONG OTHERS.THE CVB BRAIN BIOREPOSITORY HOUSES BLOOD AND SALIVA SAMPLES THAT WERE COLLECTED AS PART OF BIOMARKER STUDIES DIRECTLY SPONSORED BY COHEN VETERANS BIOSCIENCE OR THROUGH KEY PARTNERSHIP PROGRAMS. OUR BIOREPOSITORY BANKS A VARIETY OF BIOLOGIC SAMPLES INCLUDING, PLASMA, SERUM, AND SALIVA, AND WILL ENCOURAGE FUTURE COLLABORATIONS WITH RESEARCHERS FROM ACADEMIA, INDUSTRY, GOVERNMENT AND FOUNDATIONS.IN 2020, CVB COMPLETED AND PUBLISHED OUR CROSS-PLATFORM COMPARISON OF HIGHLY SENSITIVE IMMUNOASSAY TECHNOLOGIES FOR CYTOKINE MARKERS. THIS 'BAKE-OFF' STUDY IS THE FIRST IN A SERIES THAT EVALUATES THE PERFORMANCE OF FLUID-BASED ASSAYS. THE ROLE OF INFLAMMATION AND THE IMMUNE SYSTEM ACROSS NEUROPSYCHIATRIC AND NEURODEGENERATIVE DISEASES IS IMPORTANT TO UNDERSTAND, AND DEPENDS ON AN ABILITY TO MEASURE, WITH PRECISION, CYTOKINES IN THE VARIOUS FLUIDS INCLUDING BLOOD, CEREBRO-SPINAL FLUID (CSF), AND SALIVA.OUR PROGRAM BLINDLY EVALUATED FIVE LEADING IMMUNOASSAY PLATFORM'S ABILITY TO ACCURATELY AND REPRODUCIBLY MEASURE SELECTIVE ANALYTES IN PLASMA AND SERUM WERE OBTAINED FROM HEALTHY CONTROLS AND CLINICAL POPULATIONS (PTSD AND PARKINSONS). WE FOUND THAT PLATFORM PERFORMANCE WAS HIGHLY VARIABLE, PARTICULARLY FOR LOW-ABUNDANT CYTOKINES. THESE FINDINGS HIGHLIGHT WHAT METRICS SHOULD BE TAKEN INTO ACCOUNT IN SELECTING IMMUNOASSAYS IN FUTURE RESEARCH. THE PROGRAM WAS CO-FUNDED BY THE MICHAEL J FOX FOUNDATION.BRAIN-NET (TRADEMARKED):DRUG DEVELOPMENT IS COSTLY, TIME-CONSUMING, AND INEFFICIENT. MANY OPPORTUNITIES EXIST TO IMPROVE OPERATIONAL EXCELLENCE, TRIAL DESIGN, AND PATIENT RECRUITMENT. CVB IS ESTABLISHING A WELL-FUNDED, WELL-TRAINED, FAST-START, STANDING NETWORK OF BRAIN-RELATED CLINICAL TRIAL SITES WOULD PROMOTE THE DEVELOPMENT OF NEW AGENTS FOR BRAIN CONDITIONS SUCH AS PTSD, MDD, ANXIETY, CHRONIC EFFECTS OF TBI TO REDUCE TIME AND COSTS ASSOCIATED WITH DRUG DEVELOPMENT. THIS NETWORK WILL HAVE A FOCUS ON PRECISION THERAPEUTICS APPROACHES AND WILL IMPLEMENT CAPABILITIES FROM OUR OTHER PLATFORMS.BRAIN TRAUMA PROGRAMS: POST TRAUMATIC STRESS DISORDER ("PTSD") AND TRAUMATIC BRAIN INJURY ("TBI"):IN 2015, THIS CVB PROGRAM WAS FOUNDED TO ESTABLISH A NATIONAL RESEARCH ROADMAP FOR PTSD, TBI AND RELATED CONDITIONS (E.G. SUICIDALITY). BRAIN TRAUMA BLUEPRINT - STATE OF THE SCIENCE SUMMITS:THE BRAIN TRAUMA BLUEPRINT IS A SERIES OF STATE OF THE SCIENCE SUMMITS AIMED TO BUILD CONSENSUS AROUND KNOWLEDGE GAPS AND DEVELOP STRATEGIES TO MOVE THE FIELD FORWARD FOR TRAUMA-RELATED CONDITIONS BY LEVERAGING THE COMBINED INTELLECTUAL RESOURCES OF THE FULL RESEARCH COMMUNITY.THE STATE OF THE SCIENCE SUMMITS ARE DESIGNED AS RETREATS FOR 100 TO 200 STAKEHOLDERS TO COME TOGETHER TO REALIZE TRUE IMPACT. THE STAKEHOLDERS ENCOMPASS A BROAD SWATH OF THE COMMUNITY FROM ACADEMIC INSTITUTIONS TO GOVERNMENT AGENCIES, FOUNDATIONS SUPPORTING TRANSLATIONAL RESEARCH, AND INDUSTRY.EACH SUMMIT SERVES AS A LAUNCHPAD FOR ONGOING WORKING GROUPS TO DEVELOP EVIDENCE-BASED STRATEGIES AND RECOMMENDATIONS ON HOW TO FILL THOSE GAPS, IDENTIFY NEW GAPS AS OTHERS ARE FILLED, AND DISSEMINATE THESE FINDINGS BACK TO THE COMMUNITY AT LARGE THROUGH WHITE PAPERS AND PROCEEDINGS.THE INAUGURAL STATE OF THE SCIENCE, HELD IN 2018, FOCUSED ON DIAGNOSIS OF TRAUMA-RELATED BRAIN DISORDERS WITH A MAJOR FOCUS ON POST-TRAUMATIC STRESS DISORDER. THE TRAUMA-RELATED BRAIN DISORDERS RESEARCH COMMUNITY HAS IDENTIFIED A NEED TO ESTABLISH A MECHANISM-BASED TAXONOMY FOR THESE CONDITIONS TO ADVANCE BIOMARKER DISCOVERY AS WELL AS DIAGNOSIS AND THERAPEUTIC DEVELOPMENT.Desc

Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp

FieldValueIRS element (for citing)
DescA SHIFT FROM A SYNDROMIC CLASSIFICATION SYSTEM TO A MECHANISTIC ONE NECESSITATES A REVIEW OF THE CURRENT SCIENTIFIC KNOWLEDGE, ADOPTION OF NEW SCIENTIFIC MODELS, AND IDENTIFICATION OF RESEARCH AND KNOWLEDGE GAPS. THE SOSS BROUGHT TOGETHER MULTIDISCIPLINARY STAKEHOLDERS WITH DEEP SCIENTIFIC AND CLINICAL EXPERTISE TO ADDRESS THIS PRESSING NEED.THE THEME OF THE SECOND STATE OF THE SCIENCE SUMMIT, HELD IN 2019 WAS PATHS TO TREATMENT FOR TRAUMATIC BRAIN INJURY(S) WITH A FOCUS ON THE TAXONOMY AND NOSOLOGY OF THE CHRONIC SEQUELAE, CHALLENGES AND OPPORTUNITIES IN CLINICAL PRACTICE AND DEVELOPMENT, AND ETIOLOGY AND MECHANISM OF PERSISTENT SYMPTOMS. AS MEASUREMENT TOOLS ADVANCE, RESEARCH HAS BEEN ABLE TO FOCUS ON DIFFERENT TYPES OF INJURY, BEYOND THE MILD, MODERATE, AND SEVERE CLASSIFICATIONS OF TBI. TO AUGMENT AND SUPPORT THE MANY EFFORTS ACROSS FIELDS AND ORGANIZATIONS OVER THE PAST DECADE, IN 2020 WE WORKED WITH THOUGHT LEADERS ACROSS TBI TO PREPARE A CONSENSUS BLUEPRINT TO DRIVE TRANSLATIONAL SCIENCE FOR TBI, WHICH WE EXPECT TO PUBLISH IN EARLY 2021.CVB CONTINUES TO DEVELOP INNOVATIVE WAYS TO CONVENE AND ENGAGE THOUGHT LEADERS DESPITE THE LIMITATIONS ON LARGE IN-PERSON EVENTS DUE TO COVID-19. OUR EDUCATION AND ADVOCACY WORK HAS CONTINUED ON A FULLY REMOTE BASIS RESULTING IN THE ADVANCEMENT OF IMPORTANT RESEARCH AREAS, AND PLANS ARE BEING MADE FOR AN EVENT IN SUMMER 2021. ADAPTIVE PLATFORM TRIALS:CVB IS SPEARHEADING THE DESIGN AND APPLICATION OF "SMART- OR "ADAPTIVE-" CLINICAL TRIALS FOR NEUROPSYCHIATRIC AND NEURODEGENERATIVE CONDITIONS. THESE STUDIES INCLUDE A PROSPECTIVELY PLANNED OPPORTUNITY FOR MODIFICATION OF ONE OR MORE SPECIFIED ASPECTS OF THE STUDY DESIGN BASED ON DATA (USUALLY INTERIM DATA) COLLECTED FROM SUBJECTS IN THE STUDY. TO EXECUTE SUCH PROGRAMS, OUR CENTRALLY-MANAGED PLATFORM CLINICAL TRIAL INFRASTRUCTURE (BRAIN-NET) WILL BE LEVERAGED TO CONDUCT STUDIES ACROSS BRAIN CONDITIONS AND POPULATIONS INCLUDING ACADEMIC, PRIVATE, VA, AND POTENTIALLY MILITARY RESEARCH CENTERS.CURRENTLY, ONLY TWO DRUGS ARE APPROVED BY THE U.S. FOOD AND DRUG ADMINISTRATION FOR THE TREATMENT OF PTSD, ALTHOUGH BOTH ARE ONLY MODESTLY EFFECTIVE IN TREATING MILITARY-RELATED PTSD. OVER THE PAST 18 YEARS, INDIVIDUAL ACADEMIC INVESTIGATORS AND COMPANIES HAVE NOT DELIVERED ALTERNATIVE FDA-APPROVED DRUGS. IN RESPONSE TO THIS UNMET NEED, OUR PROGRAM IS DESIGNED TO TEST MULTIPLE DRUGS TO ADVANCE THEM THROUGH REGULATORY APPROVAL. IN THE FUTURE, WE ENVISION EXPANDING OUR EFFORTS TO OTHER THERAPEUTIC SOLUTIONS (E.G. DEVICES, ALTERNATIVE THERAPIES), THROUGH OUR EVIDENCE-DRIVEN CLINICAL TRIAL NETWORK INFRASTRUCTURE.BEST BIOMARKER PTSD STUDY:DESPITE THE EFFICACY OF PSYCHOTHERAPY AS FIRST-LINE TREATMENT FOR PTSD, LARGE INTER-INDIVIDUAL DIFFERENCES IN OUTCOMES EXIST, WITH ROUGHLY 50% OF PATIENTS RESPONDING TO TREATMENT AND FEWER THAN THAT FULLY REMITTING. THIS GRANT SUPPORTED THE DEVELOPMENT OF A RESPONSE DIAGNOSTIC TEST BASED ON PRELIMINARY FINDINGS FOR A COMBINATION COGNITIVE/IMAGING MARKER RESULTING FROM CVB'S INVESTMENT IN THE COHEN VETERANS CENTER STUDY AT NYU/STANFORD. THE PROGRAM INCLUDED A CLINICAL STUDY AT TWO CENTERS OF OVER 200 SUBJECTS TO REPLICATE THE INITIAL FINDING, AND IS SEEKING QUALIFICATION VIA THE FOOD AND DRUG ADMINISTRATION ("FDA") GUIDANCE TO SUPPORT THE COMMERCIALIZATION AND/OR AVAILABILITY OF THE TEST FOR CLINICAL PRACTICE AND RESEARCH AND DEVELOPMENT. THIS STUDY COMPLETED RECRUITMENT IN DECEMBER 2019 AND SEMINAL RESULTS WHICH DEMONSTRATE THAT AN EEG BASED BIOMARKER CAN PREDICT TREATMENT RESPONSE FOR INDIVIDUALS WITH PTSD OR MDD WERE PUBLISHED IN 2020.PTSD GENETICS PROGRAM:THE PSYCHIATRIC GENETICS CONSORTIUM-PTSD WORKING GROUP - BROAD INSTITUTE COLLABORATION IS SUPPORTING THE LARGEST GLOBAL GENOME WIDE ASSOCIATION STUDY ("GWAS") OF PTSD TO DATE WITH DATA FROM OVER 200,000 INDIVIDUALS ANALYZED. THE MAIN GOAL IS TO UNCOVER THE GENETIC UNDERPINNINGS OF PTSD RISK AND PUBLISH ALL RESULTS. SEMINAL FINDINGS OF THE FIRST PTSD GENETIC RISK LOCI FROM THIS PROGRAM WERE PUBLISHED IN NATURE COMMUNICATIONS IN OCTOBER 2019.IN 2020, MULTIPLE SECONDARY ANALYSES OF THIS SEMINAL DATABASED HAVE BEEN PUBLISHED:NEUROPSYCHOPHARMACOLOGY - 1/11/20 - POLYGENIC PREDICTION AND GWAS OF DEPRESSION, PTSD, AND SUICIDAL IDEATION/SELF-HARM IN A PERUVIAN COHORT.TRANSLATIONAL PSYCHIATRY - 1/20/20 - GENOMIC INFLUENCES ON SELF-REPORTED CHILDHOOD MALTREATMENT.NEUROPSYCHOPHARMACOLOGY - 3/16/20 - DISSECTING THE GENETIC ASSOCIATION OF C-REACTIVE PROTEIN WITH PTSD, TRAUMATIC EVENTS, AND SOCIAL SUPPORTCELL REPORTS - 6/2/60 - ANALYSIS OF GENETICALLY REGULATED GENE EXPRESSION IDENTIFIES A PREFRONTAL PTSD GENE, SNRNP35, SPECIFIC TO MILITARY COHORTS.SLEEP - 4/15/20 - MOLECULAR GENETIC OVERLAP BETWEEN POSTTRAUMATIC STRESS DISORDER AND SLEEP PHENOTYPESIN 2020, WE CONTINUED OUR PROGRAM WITH THE BROAD INSTITUTE TO CONDUCT FUNCTIONAL GENOMICS STUDIES OF IDENTIFIED GENETIC MARKERS AS WELL AS GENETIC EXPRESSION ANALYSIS OF AMYGDALA CELLULAR CIRCUITS IN ORDER TO INITIATE THE IDENTIFICATION OF POTENTIAL TARGETS FOR THERAPEUTIC INTERVENTION IN PTSD.NATIONAL NEUROIMAGING NORMATIVE LIBRARY PROGRAM:CVB HAS CREATED AN IMAGING REFERENCE LIBRARY ESSENTIAL TO THE DEVELOPMENT OF EFFECTIVE CLINICAL IMAGING TOOLS FOR DIAGNOSING AND MANAGING PATIENTS WITH BRAIN DISORDERS. ADVANCED NEUROIMAGING CAN NOW DETECT MICROSCOPIC CHANGES IN BRAIN STRUCTURE CAUSED BY TRAUMA OR DISEASE. THESE ADVANCED IMAGING APPROACHES INCLUDE DIFFUSION TENSOR IMAGING (DTI), FUNCTIONAL CONNECTIVITY, PERFUSION WEIGHTED IMAGING, AND VOLUMETRIC IMAGING. DESPITE THEIR PROMISE, THESE ADVANCED APPROACHES ARE CURRENTLY PRIMARILY CONFINED TO RESEARCH USE. THE NUMERICAL NATURE OF THE INFORMATION THESE ADVANCED IMAGING APPROACHES YIELD IS DIFFICULT TO TRANSLATE FROM THE STUDY OF GROUPS OF INDIVIDUALS TO A SINGLE PATIENT WITHOUT A REFERENCE. THE IMAGING DATABASE IS BASED ON THE RESULTS OF A NATIONAL STUDY OF NORMATIVE INDIVIDUALS, SPONSORED BY CVB AT UNIVERSITY OF VIRGINIA, BAYLOR UNIVERSITY AND UNIVERSITY OF UTAH AND TWO MILITARY SITES. STANDARDIZED ADVANCED NEUROIMAGING SCANS ON 3,000 ADULT VOLUNTEERS, THE RESULTING IMAGING DATA, ALONG WITH DEMOGRAPHIC INFORMATION AND THE RESULTS OF NEUROCOGNITIVE ASSESSMENTS, IS FORMING A LIBRARY DOCUMENTING POPULATION VARIATION IN BRAIN STRUCTURE AND FUNCTION AS MEASURED BY THESE ADVANCED IMAGING METHODS.THROUGH THIS IMAGING DATABASE, IT IS OUR GOAL TO ADVANCE NEUROIMAGING TO DRAMATICALLY IMPROVE THE IDENTIFICATION OF AFFECTED INDIVIDUALS AND ALLOW PHYSICIANS TO OBJECTIVELY AND EFFICIENTLY DIAGNOSE CONDITIONS SUCH AS TBI, DEMENTIA AND OTHER BRAIN DISORDERS WHERE BRAIN STRUCTURE IS DETECTED VIA MRI.PTSD AND TBI PRECLINICAL MODELING PROGRAM:ANIMAL MODELS OF PSYCHIATRIC DISORDERS OFFER A COMPLEMENTARY RESEARCH MODALITY THAT SUPPORTS CLINICAL RESEARCH. IN ORDER TO ACHIEVE A SATISFACTORY DEGREE OF VALIDITY AND RELIABILITY, ANIMAL MODELS OF COMPLEX AND INTRICATE PSYCHIATRIC DISORDERS, SUCH AS PTSD, MUST FULFILL CERTAIN CRITERIA: PATHOGENIC PROCESSES MUST BE OBSERVABLE AND MEASURABLE, AND MUST RELIABLY REFLECT CLINICAL SYMPTOMATOLOGY, AND PHARMACOLOGICAL AGENTS THAT ARE KNOWN TO AFFECT SYMPTOMS IN HUMAN SUBJECTS, SHOULD MODULATE THESE PROCESSES. CVB HAS ESTABLISHED THE ALLIANCE FOR MODELS OF PTSD, INNOVATIVE TECHNOLOGIES AND UNIFORM PRACTICES ("AMP-IT- UP") TO SUPPORT PRECLINICAL MODEL DEVELOPMENT. MULTIPLE SUB-GRANT AWARDS COMPLETED AND PUBLISHED THEIR FINDING THIS YEAR IN SUPPORT THE MISSION OF THIS PROGRAM. IN ONE OF THESE, NEW MOLECULAR PATHWAYS HAVE BEEN IDENTIFIED THAT UNDERLIE FEAR-CONDITIONING, A KEY COMPONENT OF TRAUMA-RESPONSE:NATURE COMMUNICATIONS - 10/14/20 - GENOME-WIDE TRANSLATIONAL PROFILING OF AMYGDALA CRH-EXPRESSING NEURONS REVEALS ROLE FOR CREB IN FEAR EXTINCTION LEARNING.COMPUTATIONAL MODELING & DATA SCIENCES:CVB HAS ESTABLISHED AN INTRAMURAL DATA SCIENCES PROGRAM TO BUILD MACHINE-LEARNING AND ARTIFICIAL INTELLIGENCE BASED PREDICTIVE MODELS OF DISEASE. THESE PROGRAMS BUILD ON OUR ORIGINAL ORION MS BIO-MODELLING PROGRAM AND FOCUSES ON MODELS OF PTSD, TBI, PARKINSONS AND DEMENTIA AND OTHER CONDITIONS.MULTIPLE SCLEROSIS (MS) 1.0:THE ORION BIONETWORKS FLAGSHIP PROGRAM SUCCESSFULLY PILOTED THE ESTABLISHMENT OF A MULTIPLE SCLEROSIS ("MS") BIONETWORK COMPRISED OF ACADEMIC (NEUROSCIENCE INSTITUTE OF THE BRIGHAM AND WOMEN'S HOSPITAL), ADVOCACY (ACCELERATED CURE PROJECT FOR MS), COMPUTATIONAL (GNS HEALTHCARE, METACELL, THOMSON REUTERS), INFORMATICS (CONVERGE BY DELOITTE, RANCHO BIOSCIENCES, EXAPTIVE), AND ONLINE PATIENT COMMUNITY PARTNERS (PATIENTSLIKEME [PLM]). DE-IDENTIFIED HIPPA-COMPLIANT DATA FROM THREE DATABASES WERE CURATED AND LOADED INTO A CLOUD-BASED DATA KNOWLEDGE MANAGEMENT SYSTEM. THE INTEGRATED REPOSITORY INCLUDES 9,000 SUBJECTS WITH MS AND RELATED CONDITIONS. THE ALLIANCE DEVELOPED A ROADMAP FOR JOINT EXECUTION WITH SPECIFIC SCIENTIFIC AIMS.Desc

Prog Srvc Accom Acty3 ProgSrvcAccomActy3Grp

FieldValueIRS element (for citing)
DescTHE ALLIANCE HAS GENERATED MULTIPLE MODELS BASED ON THE DATA REPOSITORY USING DIFFERENT ALGORITHMIC APPROACHES: PHENOTYPIC PROGNOSTIC MODEL AND TWO MOLECULAR PROGNOSTIC MODELS.PARKINSON'S PROGRESSION MARKERS INITIATIVE (PPMI) DATA SCIENCE MODELING GROUPEXISTING DIAGNOSES FOR COMPLEX BRAIN DISORDERS SUCH AS PARKINSON'S DISEASE (PD) FOCUS ON UNDERSTANDING CLUSTERS OF MAJOR SYMPTOMS. IN ORDER TO DRIVE PROGRESS IN THE DEVELOPMENT OF NEW TREATMENTS IT IS IMPORTANT TO UNDERSTAND THE ROLE OF SPECIFIC BIOLOGICAL PROCESSES IN DETERMINING PATIENT OUTCOMES. IN THIS PROGRAM WE MODEL THE MICHAEL J. FOX FOUNDATION (MJFF) SPONSORED PARKINSON'S PROGRESSION MODEL INITIATIVE (PPMI) STUDY. THE STUDY HAS EVALUATED PARTICIPANTS' CLINICAL STATUS WHILE COLLECTING IMAGING, BEHAVIORAL, 'OMICS AND OTHER ASSESSMENTS LONGITUDINALLY SINCE 2010. IN OUR ALIGNED MISSIONS TO ADVANCE BRAIN HEALTH, MJFF SELECTED CVB'S DATA SCIENCE TEAM TO LEVERAGE THIS COHORT TOGETHER WITH A MULTI-DISCIPLINARY APPROACH TO QUANTITATIVELY EXPLORE, EVALUATE, AND PREDICT DISEASE TRAJECTORY, RISK FACTORS, AND SUBTYPES. GIVEN THE BREADTH AND DEPTH OF THE PPMI DATA AND RICH OPPORTUNITIES TO DEVELOP IMPACTFUL DISEASE MODELS, THE TEAM USE THEIR SUBJECT MATTER EXPERTISE ACROSS TRANSLATIONAL SCIENCE TO GENERATE INSIGHTS FROM 'OMICS, IMAGING, GENETIC AND CLINICAL DATA BY INTEGRATING TECHNIQUES ACROSS ADVANCED STATISTICS, MACHINE LEARNING, AND COMPUTATIONAL MODELING TO FACILITATE PD BIOMARKER DISCOVERY AND DEEPEN OUR UNDERSTANDING OF DISEASE PROGRESSION. IN 2020, WE COMPLETED THE FIRST ANALYSES OF THESE DATA THAT WILL BE PUBLISHED SOON.PTSD & TBI KNOWLEDGEMAP (TRADEMARKED):THE BRAINTRAUMA KNOWLEDGEMAP PROJECT IS USING INFORMATION TECHNOLOGY AND VISUALIZATION TO BUILD AN INNOVATIVE NEW INTERACTIVE TOOL TO EXTRACT INFORMATION FROM PUBLISHED PAPERS FOR THE RESEARCH COMMUNITY. THE WORK INCLUDES EXTRACTION OF PTSD BIOMARKER AND TBI LITERATURE. THIS PROJECT IS PART OF OUR 'KNOWLEDGE ENGINEERING' PROGRAMMING EFFORTS TO MOVE FROM 'BIG DATA' TO 'SMART DATA'.GLOBAL PRECLINICAL DATA FORUM (TRADEMARKED):THE GLOBAL PRECLINICAL DATA FORUM (GPDF) IS A JOINTLY SPONSORED U.S. AND EUROPEAN INITIATIVE THAT ENCOURAGES GLOBAL COLLABORATION TO ADDRESS THE CHALLENGE OF ENSURING THAT PRECLINICAL RESEARCH IS REPRODUCIBLE, ROBUST AND TRANSLATABLE TO SUPPORT DISEASE RESEARCH UTILITY FOR CLINICAL RESEARCH & DEVELOPMENT (R&D). IT SUPPORTS BEST RESEARCH PRACTICES, THE DEVELOPMENT AND IMPLEMENTATION OF DATA QUALITY STANDARDS, PRECLINICAL DATA & TECHNOLOGICAL PLATFORMS, AND TRAINING PROGRAMS FOR THE NEUROSCIENCE COMMUNITY WITH THE GOAL OF ENHANCING THE DATA UTILITY DERIVED FROM PRECLINICAL MODELS. THIS IS OUR THIRD YEAR SUPPORTING WITH THE EUROPEAN COLLEGE OF NEUROPHARMACOLOGY (ECNP) THE WORLD'S FIRST NEGATIVE DATA PRIZE AS AN INCENTIVE FOR PRECLINICAL RESEARCHERS TO PUBLISH "NEGATIVE DATA" RESULTS TO ENSURE ALL NEUROSCIENCE STUDIES PROPERLY ADVANCE KNOWLEDGE. THE PRIZE IS AWARDED TO THE RESEARCHER OR RESEARCH GROUP WHOSE NEUROSCIENCE STUDY BEST EXEMPLIFIES DATA WHERE THE OUTCOMES DO NOT CONFIRM THE EXPECTED RESULTS OR WORKING HYPOTHESIS. THE AWARD WAS PRESENTED DURING THE 2020 VIRTUAL ECNP CONFERENCE.EQIPD QUALITY SYSTEM:THE GPDF AND COHEN VETERANS BIOSCIENCE ARE BOTH MAJOR CONTRIBUTORS TO THE EUROPEAN UNION INNOVATIVE MEDICINE INITIATIVE-FUNDED CONSORTIUM CALLED EQIPD (EQIPD.ORG). THE EQIPD CONSORTIUM HAS DEVELOPED A NOVEL PRECLINICAL RESEARCH QUALITY SYSTEM THAT CAN BE APPLIED IN BOTH PUBLIC AND PRIVATE SECTORS AND IS FREE FOR ANYONE TO USE. THE EQIPD QUALITY SYSTEM WAS DESIGNED TO BE SUITED TO BOOST INNOVATION BY ENSURING THE GENERATION OF ROBUST AND RELIABLE PRECLINICAL DATA WHILE BEING LEAN, EFFECTIVE AND NOT BECOMING A BURDEN THAT COULD NEGATIVELY IMPACT THE FREEDOM TO EXPLORE SCIENTIFIC QUESTIONS. EQIPD DEFINES RESEARCH QUALITY AS THE EXTENT TO WHICH RESEARCH DATA ARE FIT FOR THEIR INTENDED USE. FITNESS, IN THIS CONTEXT, IS DEFINED BY THE STAKEHOLDERS, WHO ARE THE SCIENTISTS DIRECTLY INVOLVED IN THE RESEARCH, BUT ALSO THEIR FUNDERS, SPONSORS, PUBLISHERS, RESEARCH TOOL MANUFACTURERS AND COLLABORATION PARTNERS SUCH AS PEERS IN A MULTI-SITE RESEARCH PROJECT. THE ESSENCE OF THE EQIPD QUALITY SYSTEM IS THE SET OF 18 CORE REQUIREMENTS THAT CAN BE ADDRESSED FLEXIBLY, ACCORDING TO USER-SPECIFIC NEEDS AND FOLLOWING A USER-DEFINED TRAJECTORY. THE EQIPD QUALITY SYSTEM PROPOSES GUIDANCE ON EXPECTATIONS FOR QUALITY-RELATED MEASURES, DEFINES CRITERIA FOR ADEQUATE PROCESSES (I.E., PERFORMANCE STANDARDS) AND PROVIDES EXAMPLES OF HOW SUCH MEASURES CAN BE DEVELOPED AND IMPLEMENTED. THE CONSORTIUM'S FIRST HANDBOOK PUBLISHED THIS YEAR:BESPALOV A, MICHEL MC, STECKLER T (EDS) HANDBOOK OF EXPERIMENTAL PHARMACOLOGY - GOOD RESEARCH PRACTICE IN NON-CLINICAL PHARMACOLOGY AND BIOMEDICINE, SPRINGER OPEN, CHAM, SWITZERLAND. ISBN 978-3-030-33655-4, EBOOK ISBN 978-3-030-33656-1 (2020). POLICY & ADVOCACY INITIATIVES:IN 2020, WE FORMALLY ESTABLISHED OUR DEPARTMENT OF POLICY AND ADVOCACY UNDER THE DIRECTION OF DR. CHANTELLE FERLAND-BECKHAM. WE ARE COMMITTED TO ADVOCATING FOR POLICY REFORMS AT THE FEDERAL LEVEL THAT BUILD UPON EVIDENCE-BASED PRECISION MEDICINE APPROACHES AND HAVE THE POWER TO BRING NEW SOLUTIONS FOR PTSD AND TBI IN YEARS, NOT DECADES. AS PART OF OUR ADVOCACY EFFORTS, WE CO-FOUNDED THE COALITION TO HEAL INVISIBLE WOUNDS (THE COALITION), A COLLABORATIVE INITIATIVE AIMED AT ADVOCATING FOR POLICY REFORMS TO WIDEN AND EXPEDITE THE PIPELINE FOR NEW THERAPIES AND DIAGNOSTICS FOR PTSD AND TBI-WHICH CAN BOTH DRASTICALLY INCREASE THE RISK OF SUICIDE AMONG VETERANS. THIS YEAR, WE MADE SIGNIFICANT PROGRESS ON THE COALITION'S LARGEST ADVOCACY PUSH-IMPROVING VETERANS' ACCESS TO CLINICAL TRIALS. VA CLINICAL TRIALS HAVE THE POTENTIAL TO BRING NEW PRECISION MEDICINE THERAPIES FOR PTSD AND TBI TO VETERANS, BUT VA FACILITIES OFTEN FACE CHALLENGES INITIATING AND COMPLETING CLINICAL TRIALS, MEANING THAT MANY CLINICAL TRIAL SPONSORS DO NOT ATTEMPT TO BRING TRIALS TO THE VA AND HAVE NOT DONE SO FOR YEARS. WE, LIKE MANY OTHERS, BELIEVE THAT THE VA CAN BE A LEADER IN CLINICAL RESEARCH AND HAVE COMMITTED TO SUPPORTING THE VA THROUGH THE "100 DAYS FASTER" INITIATIVE, AN INITIATIVE SPEARHEADED THROUGH OUR ADVOCACY EFFORTS WITH THE COALITION AND SUPPORTED AND ENDORSED BY BOTH THE NATIONAL ASSOCIATION OF VETERANS RESEARCH AND EDUCATION FOUNDATIONS (NAVREF) AND THE VA OFFICE OF RESEARCH AND DEVELOPMENT (ORD). EARLIER THIS YEAR, TWO OF THE COALITIONS TOP PRIORITIES OF THE "100 DAYS FASTER" INITIATIVE WERE INCORPORATED INTO A LARGER COMPREHENSIVE LEGISLATIVE PACKAGE CALLED THE COMMANDER JOHN SCOTT HANNON VETERANS MENTAL HEALTH CARE IMPROVEMENT ACT OF 2019 (S. 785). THIS IMPORTANT BILL WHICH PASSED INTO LAW IN OCTOBER, WILL IMPROVE VETERANS' ACCESS TO INNOVATIVE MENTAL HEALTH CARE AND MAKE NECESSARY INVESTMENTS INTO SUICIDE PREVENTION. CVB, AS PART OF THE COALITION, SPECIFICALLY ADVOCATED FOR FOUR PROVISIONS IN THE BILL. SECTIONS 704 AND 705 ARE AIMED AT IMPROVING VETERANS ACCESS TO CUTTING-EDGE CLINICAL TRIALS AT THE VA AS PART OF THE COALITION TO HEAL INVISIBLE WOUNDS' "100 DAYS FASTER INITIATIVE." SECTION 305 WOULD CREATE THE "PRECISION MEDICINE FOR VETERANS INITIATIVE," TO BE MODELED AFTER THE ALL OF US PRECISION MEDICINE INITIATIVE. FINALLY, SECTION 306 WOULD ENABLE THE VA TO CONDUCT ADVANCED DATA ANALYTICS, AN ESSENTIAL CAPABILITY ACROSS THE MEDICAL FIELD FOR ADVANCING RESEARCH AND IDENTIFYING NEW DIAGNOSTIC AND THERAPEUTIC CANDIDATES. AS ANOTHER IMPORTANT STEP TOWARDS "100 DAYS FASTER," CVB IS ALSO EXTENDING ITS COMMITMENT TO THE BRAIN HEALTH OF VETERANS BY SUPPORTING NAVREF AND THE NEW VA ORD-LED PARTNERED RESEARCH PROGRAM (PRP). AS AN OUTCOME OF THE ACCESS TO CLINICAL TRIALS (ACT) FOR VETERANS INITIATIVE, THE PRP INCREASES VETERANS' ACCESS TO HIGH-QUALITY CLINICAL TRIALS AND STREAMLINES THE START-UP OF NEW INNOVATIVE TRIALS, GIVING VETERANS ACCESS TO WORLD-CLASS HEALTH SOLUTIONS. THE PRP IS HELPING AGENCIES AND ORGANIZATIONS TO PARTNER MORE RAPIDLY ON CRITICAL RESEARCH TRIALS, SPECIFICALLY TARGETING THE ENHANCED INCLUSION OF VETERANS. AS A RESULT OF CRITICAL PROCESS CHANGES PUT INTO PLACE ON MARCH 3RD OF THIS YEAR, A DIRECT RECOMMENDATION OF THE "100 DAYS FASTER" INITIATIVE, WHEN THE COVID-19 PANDEMIC HIT, THE VA WAS WELL PREPARED TO MEET THE CHALLENGE AND SHOWED SIGNIFICANT PROGRESS IN INITIATING NEW CLINICAL TRIALS AT THE VA IN MERE DAYS, NOT MONTHS.Desc
FieldValueIRS element (for citing)
Total Program Service Expenses$15,387,411TotalProgramServiceExpensesAmt
Described In Section501c3Yes (1)DescribedInSection501c3Ind
Schedule B RequiredYes (1)ScheduleBRequiredInd
Political Campaign Acty0PoliticalCampaignActyInd
Lobbying ActivitiesYes (1)LobbyingActivitiesInd
Subject To Proxy Tax0SubjectToProxyTaxInd
Donor Advised Fund0DonorAdvisedFundInd
Conservation Easements0ConservationEasementsInd
Collections Of Art0CollectionsOfArtInd
Credit Counseling0CreditCounselingInd
Donor Rstr Or Quasi Endowments0DonorRstrOrQuasiEndowmentsInd
Report Land Building EquipmentYes (1)ReportLandBuildingEquipmentInd
Report Investments Other Sec0ReportInvestmentsOtherSecInd
Report Program Related Invst0ReportProgramRelatedInvstInd
Report Other Assets0ReportOtherAssetsInd
Report Other LiabilitiesYes (1)ReportOtherLiabilitiesInd
Include FIN48 FootnoteYes (1)IncludeFIN48FootnoteInd
Independent Audit Fincl StmtYes (1)IndependentAuditFinclStmtInd
Consolidated Audit Fincl Stmt0ConsolidatedAuditFinclStmtInd
School Operating0SchoolOperatingInd
Foreign OfficeYes (1)ForeignOfficeInd
Foreign ActivitiesYes (1)ForeignActivitiesInd
More Than5000 K To OrgYes (1)MoreThan5000KToOrgInd
More Than5000 K To Individuals0MoreThan5000KToIndividualsInd
Professional Fundraising0ProfessionalFundraisingInd
Fundraising Activities0FundraisingActivitiesInd
Gaming Activities0GamingActivitiesInd
Operate Hospital0OperateHospitalInd
Grants To OrganizationsYes (1)GrantsToOrganizationsInd
Grants To Individuals0GrantsToIndividualsInd
Schedule J RequiredYes (1)ScheduleJRequiredInd
Tax Exempt Bonds0TaxExemptBondsInd
Engaged In Excess Benefit Trans0EngagedInExcessBenefitTransInd
PY Excess Benefit Trans0PYExcessBenefitTransInd
Loan Outstanding0LoanOutstandingInd
Grant To Related Person0GrantToRelatedPersonInd
Business Rln With Org Mem0BusinessRlnWithOrgMemInd
Business Rln With Fam Mem0BusinessRlnWithFamMemInd
Business Rln With35 Ctrl EntYes (1)BusinessRlnWith35CtrlEntInd
Deductible Non Cash Contri0DeductibleNonCashContriInd
Deductible Art Contribution0DeductibleArtContributionInd
Terminate Operations0TerminateOperationsInd
Partial Liquidation0PartialLiquidationInd
Disregarded EntityYes (1)DisregardedEntityInd
Related Entity0RelatedEntityInd
Related Organization Ctrl Ent0RelatedOrganizationCtrlEntInd
Trnsfr Exmpt Non Chrtbl Rltd Org0TrnsfrExmptNonChrtblRltdOrgInd
Activities Conducted Prtshp0ActivitiesConductedPrtshpInd
Schedule O RequiredYes (1)ScheduleORequiredInd
IRP Document34IRPDocumentCnt
IRP Document W2 G0IRPDocumentW2GCnt
Employee35EmployeeCnt
Employment Tax Returns FiledYes (1)EmploymentTaxReturnsFiledInd
Unrelated Bus Incm Over Limit0UnrelatedBusIncmOverLimitInd
Foreign Financial Account0ForeignFinancialAccountInd
Prohibited Tax Shelter Trans0ProhibitedTaxShelterTransInd
Taxable Party Notification0TaxablePartyNotificationInd
Nondeductible Contributions0NondeductibleContributionsInd
Quid Pro Quo Contributions0QuidProQuoContributionsInd
Form8282 Property Disposed Of0Form8282PropertyDisposedOfInd
Rcv Fnds To Pay Prsnl Bnft Cntrct0RcvFndsToPayPrsnlBnftCntrctInd
Pay Premiums Prsnl Bnft Cntrct0PayPremiumsPrsnlBnftCntrctInd
Indoor Tanning Services0IndoorTanningServicesInd
Subj To Tax Rmnrtn Ex Prcht Pymt0SubjToTaxRmnrtnExPrchtPymtInd
Subject To Excs Tax Net Invst Inc0SubjectToExcsTaxNetInvstIncInd
Info In Schedule O Part VIYes (X)InfoInScheduleOPartVIInd
Governing Body Voting Members5GoverningBodyVotingMembersCnt
Independent Voting Member2IndependentVotingMemberCnt
Family Or Business Rln0FamilyOrBusinessRlnInd
Delegation Of Mgmt Duties0DelegationOfMgmtDutiesInd
Change To Org Documents0ChangeToOrgDocumentsInd
Material Diversion Or Misuse0MaterialDiversionOrMisuseInd
Members Or Stockholders0MembersOrStockholdersInd
Election Of Board Members0ElectionOfBoardMembersInd
Decisions Subject To Approva0DecisionsSubjectToApprovaInd
Minutes Of Governing BodyYes (1)MinutesOfGoverningBodyInd
Minutes Of CommitteesYes (1)MinutesOfCommitteesInd
Officer Mailing Address0OfficerMailingAddressInd
Local Chapters0LocalChaptersInd
Form990 Provided To Gvrn BodyYes (1)Form990ProvidedToGvrnBodyInd
Conflict Of Interest PolicyYes (1)ConflictOfInterestPolicyInd
Annual Disclosure Covered PrsnYes (1)AnnualDisclosureCoveredPrsnInd
Regular Monitoring EnfrcYes (1)RegularMonitoringEnfrcInd
Whistleblower PolicyYes (1)WhistleblowerPolicyInd
Document Retention PolicyYes (1)DocumentRetentionPolicyInd
Compensation Process CEOYes (1)CompensationProcessCEOInd
Compensation Process OtherYes (1)CompensationProcessOtherInd
Investment In Joint Venture0InvestmentInJointVentureInd
States Where Copy Of Return Is FldMAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldNYStatesWhereCopyOfReturnIsFldCd
Other WebsiteYes (X)OtherWebsiteInd
Upon RequestYes (X)UponRequestInd

Books In Care Of Detail BooksInCareOfDetail

Business Name BusinessName

FieldValueIRS element (for citing)
Business Name Line1GELMAN ROSENBERG AND FREEDMAN CPABusinessNameLine1Txt
FieldValueIRS element (for citing)
Phone3019519090PhoneNum

US Address USAddress

FieldValueIRS element (for citing)
Address Line14550 MONTGOMERY AVENUE SUITE 650NAddressLine1Txt
CityBETHESDACityNm
State AbbreviationMDStateAbbreviationCd
ZIP20814ZIPCd

Form990 Part VII Section A Form990PartVIISectionAGrp (13 entries)

TitleTitleTxtAverage Hours Per WeekAverageHoursPerWeekRtIndividual Trustee Or DirectorIndividualTrusteeOrDirectorIndOfficerOfficerIndReportable Comp From OrgReportableCompFromOrgAmtReportable Comp From Rltd OrgReportableCompFromRltdOrgAmtOther CompensationOtherCompensationAmtKey EmployeeKeyEmployeeIndHighest Compensated EmployeeHighestCompensatedEmployeeInd
MAGALI HAAS MD PHD
CEO & PRESIDENT60.00Yes (X)Yes (X)$635,876$0$18,315
THERESA FRANGIOSA
SECRETARY9.00Yes (X)Yes (X)$0$0$0
MICHAEL SULLIVAN
TREASURER1.00Yes (X)Yes (X)$0$0$0
DAVID BIONDI
BOARD MBR/FORMER EXECUTIVE DIR.,CLINICAL PROGRAMS40.00Yes (X)$310,381$0$28,337
DOUGLAS HAYNES
BOARD MEMBER1.00Yes (X)$0$0$0
DANIEL PLOWDEN
CHIEF FINANCIAL OFFICER40.00Yes (X)$49,221$0$5,568
ANDREAS JEROMIN PHD
CHIEF SCIENTIFIC OFFICER40.00$467,198$0$15,766Yes (X)
ALLYSON GAGE PHD
CHIEF MEDICAL OFFICER40.00$502,457$0$23,900Yes (X)
DANIELA BRUNNER PHD
FORMER EXEC. DIR. OF DIGITAL HEALTH40.00$317,293$0$10,182Yes (X)
DEEPTI COLE
ASSOCIATE DIRECTOR, DATA SCIENCE40.00$140,990$0$8,583Yes (X)
LINDA DYSON
FORMER EXECUTIVE DIRECTOR, PUBLIC AFFAIRS40.00$191,178$0$4,977Yes (X)
AMANDA NICOLE HARMON
EXECUTIVE DIRECTOR, EXTERNAL AFFAIRS40.00$231,920$0$32,407Yes (X)
FRISO POSTMA
FORMER SENIOR DIRECTOR, EARLY SIGNAL40.00$202,304$0$12,747Yes (X)
FieldValueIRS element (for citing)
Total Reportable Comp From Org$3,048,818TotalReportableCompFromOrgAmt
Tot Reportable Comp Rltd Org$0TotReportableCompRltdOrgAmt
Total Other Compensation$160,782TotalOtherCompensationAmt
Indiv Rcvd Greater Than100 K22IndivRcvdGreaterThan100KCnt
Former Ofcr Employees Listed0FormerOfcrEmployeesListedInd
Total Comp Greater Than150 KYes (1)TotalCompGreaterThan150KInd
Compensation From Other Srcs0CompensationFromOtherSrcsInd

Contractor Compensation ContractorCompensationGrp (5 entries)

Address Line1ContractorAddress/USAddress/AddressLine1TxtCityContractorAddress/USAddress/CityNmState AbbreviationContractorAddress/USAddress/StateAbbreviationCdZIPContractorAddress/USAddress/ZIPCdServicesServicesDescCompensationCompensationAmtAddress Line1ContractorAddress/ForeignAddress/AddressLine1TxtCityContractorAddress/ForeignAddress/CityNmCountryContractorAddress/ForeignAddress/CountryCd
MORGAN LEWIS AND BOCKIUS LLP
1701 MARKET STREETPHILADELPHIAPA19103LEGAL SERVICES$654,428
GRF CPA'S & ADVISORS
4550 MONTGOMERY AVENUE SUITE 800NORTH BETHESDAMD20814ACCOUNTING AND BOOKKEEPING$367,411
DEEP NET AI LTD
CHIEF INFORMATION OFFICER$314,55712 MANOR FIELDS ALREWAS BURTON ONSTRAFFORD DEDAUK
ADVANCED STRATEGIC TECHNOLOGY LLC
6 DIGITAL DRIVE UNIT 302NASHUANH03062STRATEGIC IT ADVISOR$190,108
TONE CREATIVE LLC
63 PUTNUM STREET SUITE 2020SARATOGA SPRINGSNY12866MARKETING AND DESIGN SERVICES$179,815
FieldValueIRS element (for citing)
Cntrct Rcvd Greater Than100 K16CntrctRcvdGreaterThan100KCnt
Government Grants$1,994,444GovernmentGrantsAmt
All Other Contributions$14,321,582AllOtherContributionsAmt
Total Contributions$16,316,026TotalContributionsAmt

Investment Income InvestmentIncomeGrp

FieldValueIRS element (for citing)
Total Revenue Column$154,639TotalRevenueColumnAmt
Exclusion$154,639ExclusionAmt

Total Revenue TotalRevenueGrp

FieldValueIRS element (for citing)
Total Revenue Column$16,470,665TotalRevenueColumnAmt
Related Or Exempt Func Income$0RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue$0UnrelatedBusinessRevenueAmt
Exclusion$154,639ExclusionAmt
FieldValueIRS element (for citing)
Info In Schedule O Part IXYes (X)InfoInScheduleOPartIXInd

Grants To Domestic Orgs GrantsToDomesticOrgsGrp

FieldValueIRS element (for citing)
Total$1,043,394TotalAmt
Program Services$1,043,394ProgramServicesAmt

Foreign Grants ForeignGrantsGrp

FieldValueIRS element (for citing)
Total$69,467TotalAmt
Program Services$69,467ProgramServicesAmt

Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp

FieldValueIRS element (for citing)
Total$2,230,230TotalAmt
Program Services$1,791,228ProgramServicesAmt
Management And General$432,175ManagementAndGeneralAmt
Fundraising$6,827FundraisingAmt

Other Salaries And Wages OtherSalariesAndWagesGrp

FieldValueIRS element (for citing)
Total$3,990,660TotalAmt
Program Services$3,586,290ProgramServicesAmt
Management And General$403,318ManagementAndGeneralAmt
Fundraising$1,052FundraisingAmt

Pension Plan Contributions PensionPlanContributionsGrp

FieldValueIRS element (for citing)
Total$229,268TotalAmt
Program Services$200,336ProgramServicesAmt
Management And General$28,764ManagementAndGeneralAmt
Fundraising$168FundraisingAmt

Other Employee Benefits OtherEmployeeBenefitsGrp

FieldValueIRS element (for citing)
Total$278,835TotalAmt
Program Services$238,418ProgramServicesAmt
Management And General$40,021ManagementAndGeneralAmt
Fundraising$396FundraisingAmt

Payroll Taxes PayrollTaxesGrp

FieldValueIRS element (for citing)
Total$370,527TotalAmt
Program Services$320,048ProgramServicesAmt
Management And General$50,011ManagementAndGeneralAmt
Fundraising$468FundraisingAmt

Fees For Services Management FeesForServicesManagementGrp

FieldValueIRS element (for citing)
Total$289,832TotalAmt
Management And General$289,832ManagementAndGeneralAmt

Fees For Services Legal FeesForServicesLegalGrp

FieldValueIRS element (for citing)
Total$673,696TotalAmt
Program Services$254,639ProgramServicesAmt
Management And General$419,057ManagementAndGeneralAmt

Fees For Services Accounting FeesForServicesAccountingGrp

FieldValueIRS element (for citing)
Total$515,166TotalAmt
Management And General$515,166ManagementAndGeneralAmt

Fees For Services Lobbying FeesForServicesLobbyingGrp

FieldValueIRS element (for citing)
Total$90,000TotalAmt
Program Services$90,000ProgramServicesAmt

Fees For Services Other FeesForServicesOtherGrp

FieldValueIRS element (for citing)
Total$6,664,905TotalAmt
Program Services$6,514,137ProgramServicesAmt
Management And General$132,754ManagementAndGeneralAmt
Fundraising$18,014FundraisingAmt

Office Expenses OfficeExpensesGrp

FieldValueIRS element (for citing)
Total$326,849TotalAmt
Program Services$198,468ProgramServicesAmt
Management And General$128,289ManagementAndGeneralAmt
Fundraising$92FundraisingAmt

Information Technology InformationTechnologyGrp

FieldValueIRS element (for citing)
Total$200,906TotalAmt
Program Services$139,845ProgramServicesAmt
Management And General$61,006ManagementAndGeneralAmt
Fundraising$55FundraisingAmt

Occupancy OccupancyGrp

FieldValueIRS element (for citing)
Total$580,439TotalAmt
Program Services$470,196ProgramServicesAmt
Management And General$110,243ManagementAndGeneralAmt

Travel TravelGrp

FieldValueIRS element (for citing)
Total$404,045TotalAmt
Program Services$296,367ProgramServicesAmt
Management And General$107,338ManagementAndGeneralAmt
Fundraising$340FundraisingAmt

Conferences Meetings ConferencesMeetingsGrp

FieldValueIRS element (for citing)
Total$104,052TotalAmt
Program Services$95,784ProgramServicesAmt
Management And General$8,268ManagementAndGeneralAmt

Depreciation Depletion DepreciationDepletionGrp

FieldValueIRS element (for citing)
Total$44,776TotalAmt
Program Services$37,943ProgramServicesAmt
Management And General$6,778ManagementAndGeneralAmt
Fundraising$55FundraisingAmt

Insurance InsuranceGrp

FieldValueIRS element (for citing)
Total$55,798TotalAmt
Program Services$40,851ProgramServicesAmt
Management And General$14,888ManagementAndGeneralAmt
Fundraising$59FundraisingAmt

Other Expenses OtherExpensesGrp

FieldValueIRS element (for citing)
DescBAD DEBT EXPENSEDesc
Total$75TotalAmt
Management And General$75ManagementAndGeneralAmt

Total Functional Expenses TotalFunctionalExpensesGrp

FieldValueIRS element (for citing)
Total$18,162,920TotalAmt
Program Services$15,387,411ProgramServicesAmt
Management And General$2,747,983ManagementAndGeneralAmt
Fundraising$27,526FundraisingAmt

Cash Non Interest Bearing CashNonInterestBearingGrp

FieldValueIRS element (for citing)
BOY$465,961BOYAmt
EOY$690,470EOYAmt

Savings And Temp Cash Invst SavingsAndTempCashInvstGrp

FieldValueIRS element (for citing)
BOY$16,036,550BOYAmt
EOY$15,130,098EOYAmt

Pledges And Grants Receivable PledgesAndGrantsReceivableGrp

FieldValueIRS element (for citing)
BOY$7,527,477BOYAmt
EOY$2,302,389EOYAmt

Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp

FieldValueIRS element (for citing)
BOY$61,526BOYAmt
EOY$88,022EOYAmt
FieldValueIRS element (for citing)
Land Bldg Equip Cost Or Other Bss$319,955LandBldgEquipCostOrOtherBssAmt
Land Bldg Equip Accum Deprec$35,637LandBldgEquipAccumDeprecAmt

Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp

FieldValueIRS element (for citing)
BOY$50,226BOYAmt
EOY$284,318EOYAmt

Other Assets Total OtherAssetsTotalGrp

FieldValueIRS element (for citing)
BOY$48,529BOYAmt
EOY$370,159EOYAmt

Total Assets TotalAssetsGrp

FieldValueIRS element (for citing)
BOY$24,190,269BOYAmt
EOY$18,865,456EOYAmt

Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp

FieldValueIRS element (for citing)
BOY$2,672,945BOYAmt
EOY$2,942,644EOYAmt

Grants Payable GrantsPayableGrp

FieldValueIRS element (for citing)
BOY$10,118,262BOYAmt
EOY$5,348,290EOYAmt

Deferred Revenue DeferredRevenueGrp

FieldValueIRS element (for citing)
BOY$197,714BOYAmt
EOY$9,022EOYAmt

Other Liabilities OtherLiabilitiesGrp

FieldValueIRS element (for citing)
BOY$0BOYAmt
EOY$131,804EOYAmt

Total Liabilities TotalLiabilitiesGrp

FieldValueIRS element (for citing)
BOY$12,988,921BOYAmt
EOY$8,431,760EOYAmt
FieldValueIRS element (for citing)
Organization Follows FASB117Yes (X)OrganizationFollowsFASB117Ind

No Donor Restriction Net Assets NoDonorRestrictionNetAssetsGrp

FieldValueIRS element (for citing)
BOY$840,992BOYAmt
EOY$3,045,971EOYAmt

Donor Restriction Net Assets DonorRestrictionNetAssetsGrp

FieldValueIRS element (for citing)
BOY$10,360,356BOYAmt
EOY$7,387,725EOYAmt

Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp

FieldValueIRS element (for citing)
BOY$11,201,348BOYAmt
EOY$10,433,696EOYAmt

Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp

FieldValueIRS element (for citing)
BOY$24,190,269BOYAmt
EOY$18,865,456EOYAmt
FieldValueIRS element (for citing)
Info In Schedule O Part XIYes (X)InfoInScheduleOPartXIInd
Reconcilation Revenue Expnss-$1,692,255ReconcilationRevenueExpnssAmt
Other Changes In Net Assets$924,603OtherChangesInNetAssetsAmt
Info In Schedule O Part XIIYes (X)InfoInScheduleOPartXIIInd
Method Of Accounting AccrualYes (X)MethodOfAccountingAccrualInd
Accountant Compile Or Review0AccountantCompileOrReviewInd
FS AuditedYes (1)FSAuditedInd

FS Audited Basis FSAuditedBasisGrp

FieldValueIRS element (for citing)
Separate Basis Fincl StmtYes (X)SeparateBasisFinclStmtInd
FieldValueIRS element (for citing)
Audit CommitteeYes (1)AuditCommitteeInd
Federal Grant Audit Required0FederalGrantAuditRequiredInd

Schedule A IRS990ScheduleA

FieldValueIRS element (for citing)
Public Organization170Yes (X)PublicOrganization170Ind

Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$31,399,759CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$4,366,629CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$16,828,176CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$20,795,052CurrentTaxYearMinus1YearAmt
Current Tax Year$16,316,026CurrentTaxYearAmt
Total$89,705,642TotalAmt

Total Calendar Year170 TotalCalendarYear170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$31,399,759CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$4,366,629CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$16,828,176CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$20,795,052CurrentTaxYearMinus1YearAmt
Current Tax Year$16,316,026CurrentTaxYearAmt
Total$89,705,642TotalAmt
FieldValueIRS element (for citing)
Substantial Contributors Tot$80,250,238SubstantialContributorsTotAmt
Public Support Total170$9,455,404PublicSupportTotal170Amt

Gross Investment Income170 GrossInvestmentIncome170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus2 Years$17,365CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$98,872CurrentTaxYearMinus1YearAmt
Current Tax Year$154,639CurrentTaxYearAmt
Total$270,876TotalAmt
FieldValueIRS element (for citing)
Total Support$89,976,518TotalSupportAmt
Public Support CY1700.10510PublicSupportCY170Pct
Ten Pct Facts Crcmstncs Test CYYes (X)TenPctFactsCrcmstncsTestCYInd
Facts And Circumstances TestCOHEN VETERANS BIOSCIENCE, INC. ("CVB") IS A PUBLIC CHARITY DEDICATED TO FAST-TRACKING THE DEVELOPMENT OF DIAGNOSTIC TESTS AND PERSONALIZED THERAPEUTICS FOR THE MILLIONS OF VETERANS AND CIVILIANS IN THE US WHO SUFFER THE DEVASTATING EFFECTS OF TRAUMA-RELATED AND OTHER BRAIN DISORDERS. GLOBALLY, 2 BILLION INDIVIDUALS ARE DIRECTLY AFFECTED BY BRAIN DISORDERS. THE WORLD HEALTH ORGANIZATION ATTRIBUTES 38% OF THE TOTAL YEARS LOST TO DEATH AND DISABILITY TO BRAIN DISORDERS, A FIGURE WELL AHEAD OF THE NEXT-CLOSEST AND HIGHER-PROFILE DISEASES OF CANCER (12.7%) AND CARDIOVASCULAR DISEASE (11.8%). THIS MEMO PROVIDES EVIDENCE OF QUANTITATIVE AND QUALITATIVE MEASURES WHICH SUPPORT CONTINUED PUBLIC CHARITY STATUS. CVB MEETS THE QUANTITATIVE PERCENTAGE TEST CRITERION FOR SUPPORTING FACTS AND CIRCUMSTANCES. CVB ENGAGES WITH AND MAKES AVAILABLE TO RESEARCHERS, POLICY MAKERS, AND THE GENERAL PUBLIC A BROAD ARRAY OF PROGRAMS, TOOLS, SERVICES, AND INFORMATION WHICH ADVANCE THE STATE OF BRAIN SCIENCE, GUIDED BY AN INDEPENDENT BOARD AND ADVISORY COUNSELS IN CONJUNCTION WITH CVB'S RENOWNED EXPERTS IN RELEVANT FIELDS OF NEUROSCIENCE, DATA SCIENCE AND PHARMACEUTICAL RESEARCH AND DEVELOPMENT. FOLLOWING ARE MORE DETAILED EVIDENCE OF THESE FACTS AND CIRCUMSTANCES. COHEN VETERANS BIOSCIENCE, INC. EARLY ORIGINS WERE AS AN ORGANIZATION UNDER THE FISCAL SPONSORSHIP OF THE MARIN COUNTY COMMUNITY FOUNDATION, LATER ESTABLISHED AS A STAND-ALONE 501(C)3 IN 2014 UNDER THE NAME ORION BIONETWORKS. CVB'S FOUNDER AND CEO HAS A PERSONAL CONNECTION TO THE PUBLIC WORK THE ORGANIZATION CARRIES OUT BY VIRTUE OF HER HUSBAND BEING A VETERAN OF THE US AIRFORCE SERVICE AND HER SISTER SERVING AS AN AIRFORCE COLONEL, WITH ACTIVE DEPLOYMENTS TO OEF/OIF. THE FORMAL NAME CHANGE TO COHEN VETERANS BIOSCIENCE TOOK PLACE IN 2015 IN CONCERT WITH GENEROUS SEED FUNDING FROM STEVEN A. COHEN. CVB QUALIFIES AS A PUBLIC CHARITY UNDER THE "FACTS AND CIRCUMSTANCES" TEST OF 1.170A-9(F)(3) OF THE TREASURY REGULATIONS, BASED UPON THE FOLLOWING:CVB IS ORGANIZED AND OPERATED SO AS TO ATTRACT NEW AND ADDITIONAL FUNDING ON A CONTINUOUS AND BONA FIDE BASIS; CVB HAS HAD A DONATION BUTTON ON WEBSITE AND ALL SOCIAL MEDIA SINCE INCEPTION. THE ORGANIZATION HAS RUN SEVERAL ONLINE DONATION CAMPAIGNS INCLUDING A "CROWDSOURCED" APPROACH IN 2017 THAT RAISED MORE THAN $100,000 FROM NUMEROUS INDIVIDUAL DONORS. THE ORGANIZATION HAS ACTIVELY PURSUED AND RECEIVED GRANTS FROM GOVERNMENT AND PUBLIC CHARITIES AND FOUNDATIONS FOCUSED ON BRAIN DISEASES. IN CVB'S EARLY YEARS OF EXISTENCE THE SCOPE OF ITS SOLICITATION WAS MORE LIMITED TO PERSONS DEEMED MOST LIKELY TO PROVIDE EARLY FUNDING IN AN AMOUNT SUFFICIENT TO ENABLE IT TO COMMENCE ITS CHARITABLE ACTIVITIES AND EXPAND THE SOLICITATION PROGRAM. DIRECT OUTREACH TO POTENTIAL SUPPORTERS IS INCREASINGLY CONDUCTED BY CVB'S CEO AND OTHER EXECUTIVE TEAM AND SCIENTIFIC STAFF. CVB NOW REGULARLY CONDUCTS BROAD OUTREACH CAMPAIGNS, HAS STAFF DEDICATED TO FUNDRAISING AND SUPPORTER ENGAGEMENT TO SOLICIT CHARITABLE CONTRIBUTIONS FROM THE GENERAL PUBLIC, AND CARRIES ON ACTIVITIES DESIGNED TO ATTRACT SUPPORT FROM GOVERNMENT SOURCES AND PUBLIC CHARITIES. IN THE MOST RECENT FISCAL YEAR CVB HIRED AN EXPERIENCED EXECUTIVE DIRECTOR OF DEVELOPMENT TO FURTHER EXPAND FUNDRAISING INFRASTRUCTURE AND OUTREACH. CVB REGULARLY APPLIES FOR RELEVANT FUNDING FROM GOVERNMENT AGENCIES AND NONPROFIT ORGANIZATIONS. CVB HAS DEVELOPED MATERIALS TO SUPPORT POTENTIAL DONOR ENGAGEMENT, AND WORKS DILIGENTLY TO EXPAND THE NETWORK OF POTENTIAL SUPPORTERS BY ENGAGING WITH BOARD MEMBERS AND STAFF TO CONNECT WITH THEM. CVB'S PUBLIC SUPPORT PERCENTAGE, AS REPORTED FOR 2019, IS 10.51%, AND IS EXPECTED TO INCREASE AS A RESULT OF EXPANDED FUNDRAISING INFRASTRUCTURE AND OUTREACH. THE 2019 RESULT WHEN COMPARED TO THE 2018 PERCENTAGE OF 8.94% IS EVIDENCE OF THE INCREASING BREADTH OF PUBLIC SUPPORT AS CVB FURTHER BUILDS UPON ITS FUNDRAISING EFFORTS. CVB HAS RECEIVED SUPPORT FROM A DIVERSITY OF DONORS AND SOURCES DURING ITS INITIAL START-UP PERIOD AND WILL CONTINUE TO EXPAND ITS DONOR BASE. DONORS INCLUDE US GOVERNMENT AGENCIES SUCH AS THE NATIONAL INSTITUTES OF HEALTH AND THE DEPARTMENT OF DEFENSE; A NUMBER OF NONPROFIT ORGANIZATIONS AND FOUNDATIONS INTERESTED IN MEDICAL RESEARCH AND ISSUES IMPACTING VETERANS; AND MORE THAN 100 INDIVIDUAL DONORS. CVB'S CURRENT FUNDRAISING PLANS ARE TARGETED AT A BROAD BASE OF DONORS, INCLUDING FOUNDATIONS, INDIVIDUALS, AND GOVERNMENT AGENCIES. AS EVIDENCED BY THE EXTENSIVE PROGRAMS SPONSORED BY CVB SUPPORTING RESEARCH COLLABORATIONS AND SCIENTIFIC BEST PRACTICE ADOPTION, CVB REMAINS AN ORGANIZATION COMMITTED TO SERVING THE PUBLIC THROUGH ITS WORK. EXAMPLES WHICH DEMONSTRATE OUR COMMITMENT TO THE PUBLIC BENEFIT AND PUBLIC PARTICIPATION IN OUR EFFORTS INCLUDE CVB'S VETERANS ADVISORY COUNCIL, STATE OF THE SCIENCE SUMMITS, NUMEROUS EXPERT WORKSHOPS, ENSURING OUR RESEARCH IS PUBLISHED IN OPEN ACCESS PUBLICATIONS, AND DATA SHARING POLICIES ENCOURAGING RESEARCH COLLABORATION ACROSS ORGANIZATIONAL BOUNDARIES. CVB PROGRAM ACTIVITIES, WITH TEAM SCIENCE AND COLLABORATION AS A CORE BELIEF, PROVIDES DIRECT PUBLIC BENEFIT THROUGH ITS RESEARCH AND EDUCATIONAL ACTIVITIES. CVB SPEARHEADS RESEARCH WITH MULTI-SECTOR PARTNERS INCLUDING ACADEMIA, GOVERNMENT, FOUNDATION RESEARCH, AND INDUSTRY ORGANIZATIONS TO ADVANCE COLLECTIVE UNDERSTANDING OF AND APPROACHES TO IMPROVING BRAIN HEALTH. FOR EXAMPLE, CVB CO-SPONSORED THE PSYCHIATRIC GENETICS CONSORTIUM WITH THE BROAD INSTITUTE, THE LARGEST GENOME-WIDE ASSOCIATION STUDY META-ANALYSIS OF POST-TRAUMATIC STRESS DISORDER (PTSD) TO DATE. USING A MULTI-ETHNIC COHORT THAT INCLUDES OVER 30,000 PTSD CASES, 170,000 CONTROLS AND IS OVER TEN TIMES THE SIZE OF ANY PREVIOUS ANALYSIS, SIX GENETIC MARKERS FOR PTSD RISK WERE NEWLY DISCOVERED. CVB ALSO BROADLY DISSEMINATES RESEARCH AND EDUCATIONAL INFORMATION ABOUT PTSD, TRAUMATIC BRAIN INJURY (TBI) AND SUICIDE DIRECTLY TO THE PUBLIC THROUGH ITS WEBSITE AND SOCIAL MEDIA. THE INFORMATION IS PROVIDED IN AN ACCESSIBLE AND UNDERSTANDABLE FORMAT FOR ANY NON-MEDICAL READER, HELPING VETERANS AND OTHERS SUFFERING FROM PTSD OR TBI TO UNDERSTAND THEIR CONDITIONS AND THE SYMPTOMS AND CAUSES ASSOCIATED WITH THEM. THESE MATERIALS ALSO SERVE TO EDUCATE THE PUBLIC ABOUT PTSD AND TBI AND THE EFFECTS OF THESE CONDITIONS ON OUR VETERANS AND FAMILIES. THESE EVENTS, PROCEEDINGS, AND OTHER EDUCATIONAL OUTREACH SERVE TO ADVANCE BRAIN SCIENCE IN THE PUBLIC INTEREST. SEE WWW.COHENVETERANSBIOSCIENCE.ORG AND THE FORM 990 PROGRAM DESCRIPTIONS FOR MORE DETAILS ON THE EXPANSIVE NATURE OF THESE PROGRAMS. CVB ALSO ENLISTS THE ACTIVE SUPPORT AND PARTICIPATION OF EXPERTS, PUBLIC OFFICIALS, AND COMMUNITY LEADERS. CVB'S VETERANS ADVISORY COUNCIL ("VAC") INCLUDES SENIOR LEADERS WHO SERVED IN MILITARY LEADERSHIP ROLES AND/OR HAVE VETERAN FAMILY MEMBERS AND HAVE A DEEP PERSONAL COMMITMENT TO VETERANS' CONCERNS RELATED TO BRAIN HEALTH. VAC HELPS REPRESENT, ADVOCATE AND SUPPORT MILITARY AND VETERANS' INTERESTS TO CVB TO AID CVB IN DELIVERING MEANINGFUL RESULTS FOR VETERANS THROUGH DATA-DRIVEN SCIENCE AND ADVOCACY. MORE INFORMATION ABOUT VAC IS AVAILABLE HERE: HTTPS://WWW.COHENVETERANSBIOSCIENCE.ORG/VETERANS-ADVISORY-COUNCIL/ FINALLY, CVB HAS A REPRESENTATIVE GOVERNING BODY THROUGH ITS UNCOMPENSATED BOARD OF DIRECTORS CONSISTING OF FIVE MEMBERS WITH EQUAL VOTING RIGHTS. FOUR OF THE FIVE MEMBERS ARE INDEPENDENT OF THE LARGEST DONOR. ALL OF THE BOARD MEMBERS ARE INDIVIDUALS WITH SPECIAL KNOWLEDGE AND EXPERTISE RELEVANT TO THE ORGANIZATION'S CHARITABLE ACTIVITIES IN BRAIN SCIENCE AND HEALTH, AS WELL AS MEMBERS WITH LONGSTANDING DEDICATION TO THE NEEDS OF VETERANS AND OTHERS WHO SUFFER FROM BRAIN DISEASES THROUGH BOTH PAID AND UNPAID WORK WITH GOVERNMENT AND OTHER NONPROFIT AGENCIES. THE QUALIFICATIONS OF THE BOARD MEMBERS INCLUDE: BOARD CHAIR AND CEO, MAGALI HAAS, MD, PHD FOUNDED ORION BIONETWORKS (RENAMED TO COHEN VETERANS BIOSCIENCE IN 2015) WITH SPONSORSHIP FROM JANSSEN RESEARCH & DEVELOPMENT TO UNLOCK THE POWER OF SHARED DATA AND PREDICTIVE MODELING TO HELP TRANSFORM OUR UNDERSTANDING OF BRAIN DISEASES AND ACCELERATE THE SEARCH FOR CURES.DR. HAAS HAS OVER 20 YEARS OF PHARMACEUTICAL EXECUTIVE AND CLINICAL RESEARCH EXPERIENCE INCLUDING DEVELOPMENT LEADERSHIP ROLES IN MEDICAL MARKETING, FULL CLINICAL DEVELOPMENT, EARLY DEVELOPMENT, AND TRANSLATIONAL AND BIOMARKER SCIENCES IN PSYCHIATRY AND NEUROLOGY. DURING HER TENURE AT JOHNSON & JOHNSON, SHE SUCCESSFULLY FILED NDAS IN THE US AND EUROPE FOR RISPERIDONE INDICATIONS IN AUTISM, ADOLESCENT SCHIZOPHRENIA, JUVENILE BIPOLAR DISORDER AND CONDUCT DISORDERS. SHE ALSO LED DEVELOPMENT TEAMS EVALUATING COMPOUNDS FOR DEPRESSION, NEUROPATHIC PAIN, EPILEPSY, AND MIGRAINE DISORDER.FactsAndCircumstancesTestTxt

Form990 Schedule A Part VI Form990ScheduleAPartVIGrp

FieldValueIRS element (for citing)
Form And Line ReferencePART II SECT C LINE 17A FACTS & CIRCUMSTANCES TEST (CONT):FormAndLineReferenceDesc
ExplanationSHE SERVED 3 YEARS AS CHIEF SCIENCE AND TECHNOLOGY OFFICER FOR ONE MIND FOR RESEARCH, A NONPROFIT ORGANIZATION LAUNCHED IN MAY 2012 BY PATRICK J KENNEDY. SHE ORCHESTRATED THE LAUNCH OF ONE MIND'S SEMINAL PROGRAMS, APOLLO, AN INFORMATICS RESEARCH PORTAL AND, GEMINI, AN INTERNATIONAL TBI/PTSD RESEARCH PROGRAM. AS AN "INTRAPRENEUR" AT J&J SHE ESTABLISHED THE FIRST NEUROSCIENCE TRANSLATIONAL MEDICINE & INTEGRATIVE SOLUTIONS DEPARTMENT, AND CO-FOUNDED THE FIRST COMPANION DIAGNOSTICS CENTER OF EXCELLENCE AS WELL AS J&J'S HEALTHCARE INNOVATION TEAM. SHE SERVES ON SEVERAL ADVISORY BOARDS INCLUDING ALTO NEUROSCIENCE, KREMBIL CENTRE FOR NEUROINFORMATICS, VIRTUALBRAINCLOUD, PARTNERSHIP FOR ASSESSMENT AND ACCREDITATION OF SCIENTIFIC PRACTICE (PAASP) AND INTERUNIVERSITY MICROELECTRONICS CENTRE (IMEC) AN INTERNATIONAL RESEARCH & DEVELOPMENT AND INNOVATION HUB. DR. HAAS EARNED HER BS IN BIOENGINEERING FROM THE UNIVERSITY OF PENNSYLVANIA, AN MS IN BIOMEDICAL ENGINEERING FROM RUTGERS UNIVERSITY, NEW JERSEY, AND HER MD PHD WITH DISTINCTION IN NEUROSCIENCE FROM ALBERT EINSTEIN COLLEGE OF MEDICINE, NEW YORK. BOARD MEMBER, SECRETARY, THERESA FRANGIOSA HAS EXTENSIVE EXECUTIVE EXPERIENCED BASED ON HER 25 YEAR CAREER WITH THE PHARMACEUTICAL SECTOR. IN HER ROLES WITHIN PHARMA, SHE WAS A GLOBAL LAUNCH LEADER AS WELL AS OVERSEEING EARLY COMMERCIAL STRATEGY IN NEUROSCIENCES. SHE LED LARGE SCALE TEAMS, CROSS-FUNCTIONAL TEAMS TO DEFINE DISEASE AND THERAPEUTIC AREA STRATEGIES FOR JANSSEN AND GLAXOSMITHKLINE. SHE HAS ALSO LED INDICATION PRIORITIZATION EFFORTS AND DEVELOPMENT OF OVER 200 TARGET PRODUCT PROFILES OVER A VARIETY OF DISEASE STATES, LEVERAGING WELL-ESTABLISHED PROCESSES AND FRAMEWORKS, INCLUDING DEEPER UNDERSTANDING OF PATIENT JOURNEYS TO CREATE KEY INSIGHTS. SHE HAS APPLIED HER PROFESSIONAL CAREER EXPERIENCE AND HER PASSION FOR ADVOCACY TO HELP CREATE A CHANNEL FOR FEEDBACK FROM THOSE DIAGNOSED WITH OR AT RISK FOR ALZHEIMER'S DISEASE OR DEMENTIA, THEIR CARE PARTNERS AND INDIVIDUALS WHO ARE 'WORRIED WELL', CALLED THE A-LIST. SHE IS THE LEAD INVESTIGATOR FOR THIS RESEARCH STUDY WITH IRB OVERSIGHT. MS. FRANGIOSA OBTAINED HER BACHELOR OF ADMINISTRATION, ACCOUNTING CONCENTRATION FROM URSINUS COLLEGE (COLLEGEVILLE, PA) IN 1988 AND HER MASTERS OF BUSINESS ADMINISTRATION, PHARMACEUTICAL MARKETING FROM ST. JOSEPH'S UNIVERSITY IN 1996. BOARD MEMBER, DAVID BIONDI, MD HAS OVER 20 YEARS OF CLINICAL EXPERIENCE IN MEDICAL PRACTICE AND HELD MEDICAL DIRECTORSHIPS AT THE US NAVAL HOSPITAL IN OKINAWA JAPAN, THE PAIN MANAGEMENT PROGRAM & HEADACHE INSTITUTE AT MARYVIEW MEDICAL CENTER IN PORTSMOUTH VA, THE PAIN DIVISION OF THE MICHIGAN HEAD PAIN & NEUROLOGICAL INSTITUTE IN ANN ARBOR MI, AND THE INTERDISCIPLINARY HEADACHE & PAIN REHABILITATION PROGRAM AT SPAULDING REHABILITATION HOSPITAL IN BOSTON MA. HE WAS PREVIOUSLY AN ASSISTANT NEUROLOGIST AT THE MASSACHUSETTS GENERAL HOSPITAL AND AN INSTRUCTOR IN NEUROLOGY AT HARVARD MEDICAL SCHOOL. DR. BIONDI SERVED AS A TRUSTEE FOR THE UNIVERSITY OF NEW ENGLAND AND WAS CHAIR OF ITS ACADEMIC AND RESEARCH AFFAIRS COMMITTEE AND VICE-CHAIR OF ITS LONG-RANGE PLANNING COMMITTEE. HE ALSO SERVED AS A DIRECTOR AND MEDICAL ADVISOR FOR THE AFTER ACTION NETWORK, A NONPROFIT VETERAN SERVICE ORGANIZATION IN KANSAS CITY MO. HE IS A FELLOW OF THE AMERICAN ACADEMY OF NEUROLOGY. DR. BIONDI HAS OVER 15 YEARS OF EXPERIENCE IN CLINICAL RESEARCH AND DEVELOPMENT OF PHARMACEUTICALS AND MEDICAL DEVICES IN THE NEUROLOGY, PSYCHIATRY, AND PAIN THERAPEUTIC AREAS. HIS EXPERIENCES INCLUDE THE DESIGN, IMPLEMENTATION, MONITORING, AND INTERPRETATION OF PHASE 2 TO PHASE 4 CLINICAL TRIALS AND IN-HOUSE AND FIELD-BASED ACTIVITIES ASSOCIATED WITH INSIGHTS GENERATION, NEW BUSINESS OPPORTUNITIES, EMERGING HEALTH POLICY, KNOWLEDGE TRANSLATION AND IMPLEMENTATION, AND ORGANIZATIONAL EFFECTIVENESS. HE PREVIOUSLY SERVED AS EXECUTIVE DIRECTOR FOR CLINICAL PROGRAMS WITH COHEN VETERANS BIOSCIENCE. DR. BIONDI RECEIVED HIS MEDICAL DEGREE FROM THE UNIVERSITY OF NEW ENGLAND, COLLEGE OF OSTEOPATHIC MEDICINE IN BIDDEFORD ME. HE COMPLETED RESIDENCY TRAINING IN NEUROLOGY AT THE NATIONAL NAVAL MEDICAL CENTER IN BETHESDA MD AND IS BOARD-CERTIFIED IN NEUROLOGY WITH SUBSPECIALTY EXPERTISE IN HEADACHE AND PAIN MEDICINE. HE RECEIVED HIS BACHELOR OF SCIENCE - MAGNA CUM LAUDE IN PHARMACY FROM THE LONG ISLAND UNIVERSITY, SCHWARTZ COLLEGE OF PHARMACY & HEALTH SCIENCE IN BROOKLYN NY. BOARD MEMBER, TREASURER, MICHAEL C. SULLIVAN IS THE CHIEF OF STAFF AND HEAD OF EXTERNAL AFFAIRS OF POINT72 ASSET MANAGEMENT. MR. SULLIVAN PREVIOUSLY SERVED AS A SENIOR AIDE IN THE UNITED STATES SENATE, FOCUSING ON TELECOM, TECHNOLOGY, AND FINANCE ISSUES. MR. SULLIVAN ALSO SERVED AS A STAFF MEMBER IN THE U.S. HOUSE OF REPRESENTATIVES WORKING ON SIMILAR ISSUES. BEFORE COMING TO CAPITOL HILL, MR. SULLIVAN WAS THE HEAD OF STRATEGIC DEVELOPMENT FOR A TELECOMMUNICATIONS FOCUSED TRADE ASSOCIATION. MR. SULLIVAN IS INVOLVED WITH SEVERAL VETERANS' MENTAL HEALTH-RELATED NON-PROFIT ORGANIZATIONS. HE HELPED ESTABLISH AND SERVES ON THE BOARD AND AS TREASURER OF THE COHEN VETERANS NETWORK, WHICH OPERATES A NATIONAL NETWORK OF CLINICS TO TREAT VETERANS AND THEIR FAMILY MEMBERS AFFECTED BY POST-TRAUMATIC STRESS. MR. SULLIVAN IS AN ASSOCIATE AT THE NYU-STERN ENDLESS FRONTIER LABS, WHERE HE MENTORS START-UP COMPANIES IN ARTIFICIAL INTELLIGENCE, MACHINE LEARNING, AND RELATED FIELDS. HE IS ALSO A MEMBER OF THE EXECUTIVE COMMITTEE OF STUDENTS FIRST NEW YORK, A NONPROFIT ORGANIZATION ADVOCATING FOR EDUCATIONAL REFORM IN NEW YORK STATE. MR. SULLIVAN IS A GRADUATE OF VANDERBILT UNIVERSITY. BOARD MEMBER, DOUG HAYNES IS AN ACTIVE COMMUNITY MEMBER, DEDICATING A SIGNIFICANT PORTION OF HIS EFFORTS TO SUPPORTING VETERANS' INITIATIVES. IN ADDITION TO SERVING ON THE BOARD OF THE ROBIN HOOD FOUNDATION, MR. HAYNES HELPED LAUNCH ITS VETERANS ADVISORY BOARD WHICH RAISED OVER $12 MILLION TO SUPPORT THE INCREASE IN VETERANS RETURNING FROM IRAQ AND AFGHANISTAN, AND ALSO WORKS WITH NEW YORK-BASED COMPANIES TO CREATE MORE JOB OPPORTUNITIES FOR VETERANS. MR. HAYNES SERVES ON THE CORPORATE ADVISORY BOARD OF THE DARDEN GRADUATE SCHOOL OF BUSINESS, THE BOARD OF THE CANTERBURY SCHOOL, SINGTEL'S TECHNOLOGY ADVISORY BOARD, AND THE BOARD OF THE CENTER FOR GLOBAL ENTERPRISE. MR. HAYNES FORMERLY SERVED AS THE PRESIDENT OF POINT72 ASSET MANAGEMENT, L.P., ORIGINALLY JOINING THE FIRM AS MANAGING DIRECTOR OF HUMAN CAPITAL IN FEBRUARY 2014. PRIOR TO JOINING POINT72, MR. HAYNES WAS A DIRECTOR AT MCKINSEY & COMPANY. BEFORE JOINING MCKINSEY, MR. HAYNES WORKED FOR THE CENTRAL INTELLIGENCE AGENCY AND THEN GE'S ADVANCED MATERIALS BUSINESS. MR. HAYNES EARNED A BS SUMMA CUM LAUDE IN MECHANICAL ENGINEERING FROM WEST VIRGINIA UNIVERSITY, AND RECEIVED HIS MBA AT THE UNIVERSITY OF VIRGINIA'S DARDEN GRADUATE BUSINESS SCHOOL, WHERE HE WAS A SHERMET SCHOLAR.ExplanationTxt

Schedule B IRS990ScheduleB

Contributor Information ContributorInformationGrp

FieldValueIRS element (for citing)
ContributorRESTRICTEDContributorNum

Contributor Business Name ContributorBusinessName

FieldValueIRS element (for citing)
Business Name Line1RESTRICTEDBusinessNameLine1

Contributor US Address ContributorUSAddress

FieldValueIRS element (for citing)
Address Line1RESTRICTEDAddressLine1
Address Line2RESTRICTEDAddressLine2
CityRESTRICTEDCity
StateRESTRICTEDState
ZIP CodeRESTRICTEDZIPCode
FieldValueIRS element (for citing)
Total ContributionsRESTRICTEDTotalContributionsAmt

Schedule C IRS990ScheduleC

Total Direct Lobbying TotalDirectLobbyingGrp

FieldValueIRS element (for citing)
Filing Organizations Total$90,000FilingOrganizationsTotalAmt

Total Lobbying Expend TotalLobbyingExpendGrp

FieldValueIRS element (for citing)
Filing Organizations Total$90,000FilingOrganizationsTotalAmt

Other Exempt Purpose Expend OtherExemptPurposeExpendGrp

FieldValueIRS element (for citing)
Filing Organizations Total$18,072,920FilingOrganizationsTotalAmt

Total Exempt Purpose Expend TotalExemptPurposeExpendGrp

FieldValueIRS element (for citing)
Filing Organizations Total$18,162,920FilingOrganizationsTotalAmt

Lobbying Nontaxable Amount LobbyingNontaxableAmountGrp

FieldValueIRS element (for citing)
Filing Organizations Total$1,000,000FilingOrganizationsTotalAmt

Grassroots Nontaxable GrassrootsNontaxableGrp

FieldValueIRS element (for citing)
Filing Organizations Total$250,000FilingOrganizationsTotalAmt

Tot Lbbyng Grassroot Mns Non Tx TotLbbyngGrassrootMnsNonTxGrp

FieldValueIRS element (for citing)
Filing Organizations Total$0FilingOrganizationsTotalAmt

Tot Lbby Expend Mns Lbbyng Non Tx TotLbbyExpendMnsLbbyngNonTxGrp

FieldValueIRS element (for citing)
Filing Organizations Total$0FilingOrganizationsTotalAmt

Avg Lobbying Nontaxable Amount AvgLobbyingNontaxableAmountGrp

FieldValueIRS element (for citing)
Current Year Minus2$893,383CurrentYearMinus2Amt
Current Year Minus1$1,000,000CurrentYearMinus1Amt
Current Year$1,000,000CurrentYearAmt
Total$2,893,383TotalAmt
FieldValueIRS element (for citing)
Lobbying Ceiling$4,340,075LobbyingCeilingAmt

Avg Total Lobbying Expend AvgTotalLobbyingExpendGrp

FieldValueIRS element (for citing)
Current Year Minus2$90,000CurrentYearMinus2Amt
Current Year Minus1$87,500CurrentYearMinus1Amt
Current Year$90,000CurrentYearAmt
Total$267,500TotalAmt

Avg Grassroots Nontaxable AvgGrassrootsNontaxableGrp

FieldValueIRS element (for citing)
Current Year Minus2$223,346CurrentYearMinus2Amt
Current Year Minus1$250,000CurrentYearMinus1Amt
Current Year$250,000CurrentYearAmt
Total$723,346TotalAmt
FieldValueIRS element (for citing)
Grassroots Ceiling$1,085,019GrassrootsCeilingAmt

Schedule D IRS990ScheduleD

Leasehold Improvements LeaseholdImprovementsGrp

FieldValueIRS element (for citing)
Other Cost Or Other Basis$134,362OtherCostOrOtherBasisAmt
Depreciation$9,834DepreciationAmt
Book Value$124,528BookValueAmt

Equipment EquipmentGrp

FieldValueIRS element (for citing)
Other Cost Or Other Basis$174,076OtherCostOrOtherBasisAmt
Depreciation$19,405DepreciationAmt
Book Value$154,671BookValueAmt

Other Land Buildings OtherLandBuildingsGrp

FieldValueIRS element (for citing)
Other Cost Or Other Basis$11,517OtherCostOrOtherBasisAmt
Depreciation$6,398DepreciationAmt
Book Value$5,119BookValueAmt
FieldValueIRS element (for citing)
Total Book Value Land Buildings$284,318TotalBookValueLandBuildingsAmt

Other Liabilities Org OtherLiabilitiesOrgGrp

FieldValueIRS element (for citing)
DescDEFERRED RENTDesc
Amt$131,804Amt
FieldValueIRS element (for citing)
Total Liability$131,804TotalLiabilityAmt
Footnote TextYes (X)FootnoteTextInd
Total Rev Etc Audited Fincl Stmt$16,470,665TotalRevEtcAuditedFinclStmtAmt
Revenue Not Reported$0RevenueNotReportedAmt
Revenue Subtotal$16,470,665RevenueSubtotalAmt
Revenue Not Reported Fincl Stmt$0RevenueNotReportedFinclStmtAmt
Total Revenue Per Form990$16,470,665TotalRevenuePerForm990Amt
Tot Expns Etc Audited Fincl Stmt$18,162,920TotExpnsEtcAuditedFinclStmtAmt
Expenses Not Reported$0ExpensesNotReportedAmt
Expenses Subtotal$18,162,920ExpensesSubtotalAmt
Expenses Not Rpt Fincl Stmt$0ExpensesNotRptFinclStmtAmt
Total Expenses Per Form990$18,162,920TotalExpensesPerForm990Amt

Supplemental Information Detail SupplementalInformationDetail

FieldValueIRS element (for citing)
Form And Line ReferencePART X, LINE 2:FormAndLineReferenceDesc
ExplanationTAX POSITION: THE ORGANIZATION CURRENTLY EVALUATES ALL TAX POSITIONS, AND MAKES A DETERMINATION REGARDING THE LIKELIHOOD OF THOSE POSITIONS BEING UPHELD UNDER REVIEW. THE PRIMARY TAX POSITION MADE BY THE ORGANIZATION IS THE EXISTENCE OF UNRELATED BUSINESS INCOME TAX AND THE ORGANIZATION'S STATUS AS A TAX-EXEMPT ORGANIZATION UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE. FOR THE YEAR PRESENTED, THE ORGANIZATION HAS NOT RECOGNIZED ANY TAX BENEFITS OR LOSS CONTINGENCIES FOR UNCERTAIN TAX POSITIONS BASED ON THIS EVALUATION.ExplanationTxt

Schedule F IRS990ScheduleF

FieldValueIRS element (for citing)
Grant Records MaintainedYes (1)GrantRecordsMaintainedInd

Account Activities Outside US AccountActivitiesOutsideUSGrp (2 entries)

RegionRegionTxtOfficesOfficesCntEmployeeEmployeeCntType Of Activities ConductedTypeOfActivitiesConductedTxtSpecific Services ProvidedSpecificServicesProvidedTxtRegion Total ExpendituresRegionTotalExpendituresAmt
EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM00GRANTS TO RECIPIENTS LOCATED IN REGIONN/A$69,467
EUROPE (INCLUDING ICELAND & GREENLAND)01CHIEF INFORMATION OFFICERN/A$322,771
FieldValueIRS element (for citing)
Subtotal Offices0SubtotalOfficesCnt
Subtotal Employees1SubtotalEmployeesCnt
Continuation Total Office0ContinuationTotalOfficeCnt
Continuation Total Employee0ContinuationTotalEmployeeCnt
Total Office0TotalOfficeCnt
Total Employee1TotalEmployeeCnt
Subtotal Spent$392,238SubtotalSpentAmt
Continuation Spent$0ContinuationSpentAmt
Total Spent$392,238TotalSpentAmt

Grants To Org Outside US GrantsToOrgOutsideUSGrp (2 entries)

RegionRegionTxtPurpose Of GrantPurposeOfGrantTxtCash GrantCashGrantAmtManner Of Cash DisbursementMannerOfCashDisbursementTxtDescription Of Non Cash AsstDescriptionOfNonCashAsstTxtValuation Method UsedValuationMethodUsedDesc
EUROPE (BELGIUM)HIGH-DENSITY RECORDING IN THE SPS MODEL OF PTSD$29,467WIRE TRANSFERN/AN/A
EUROPE (GREECE)PLATFORM FOR THE EXCHANGE OF EXPERIMENTAL RESEARCH STANDARDS (PEERS)$40,000WIRE TRANSFERN/AN/A
FieldValueIRS element (for citing)
Total501c3 Org1Total501c3OrgCnt
Total Other Org1TotalOtherOrgCnt
Transfer To Foreign Corp0TransferToForeignCorpInd
Interest In Foreign Trust0InterestInForeignTrustInd
Foreign Corp Ownership0ForeignCorpOwnershipInd
Passive Foreign Investmest Co0PassiveForeignInvestmestCoInd
Foreign Partnership0ForeignPartnershipInd
Boycott Countries0BoycottCountriesInd

Supplemental Information Detail SupplementalInformationDetail (2 entries)

Form And Line ReferenceFormAndLineReferenceDescExplanationExplanationTxt
PART I, LINE 2:THE ORGANIZATION REQUIRES GRANTEES TO REGULARLY PROVIDE QUALITATIVE AND QUANTITATIVE REPORTS DESCRIBING HOW FUNDS ARE BEING SPENT AND THE RESULTS THE GRANTEE HAS ACHIEVED. PROGRESS IS MEASURED AGAINST ORIGINAL AND REVISED GRANT PROPOSALS. CONTINUATION OF FUNDING IS DEPENDENT ON RESULTS AND ACCURATE, TIMELY REPORTING.
PART III ACCOUNTING METHOD:

Schedule I IRS990ScheduleI

FieldValueIRS element (for citing)
Grant Records MaintainedYes (1)GrantRecordsMaintainedInd

Recipient Table RecipientTable (8 entries)

Address Line1USAddress/AddressLine1TxtCityUSAddress/CityNmState AbbreviationUSAddress/StateAbbreviationCdZIPUSAddress/ZIPCdRecipient EINRecipientEINIRC SectionIRCSectionDescCash GrantCashGrantAmtValuation Method UsedValuationMethodUsedDescNon Cash AssistanceNonCashAssistanceDescPurpose Of GrantPurposeOfGrantTxtNon Cash AssistanceNonCashAssistanceAmt
CHILDREN'S HOSPITAL OF PHILADELPHIA
PO BOX 8500PHILADEPHIAPA19178231352166501(C)3$60,000N/AN/AVALIDATING CONSTRUCTS RELEVANT TO PTSD IN A MODEL OF INDIVIDUAL DIFFERENCES IN RESPONSE TO SOCIAL DEFEAT IN RATS
MHEALTHFORWARD INC
315 W 36TH STNEW YORKNY10018813198566501(C)3$60,000N/AN/ABIOSENSORS AND MOBILE HEALTH PLATFORM FOR BRAIN DISEASES
AMERICAN COLLEGE OF RADIOLOGY (ACR)
1818 MARKET ST STE 1720PHILADELPHIAPA19103362261602501(C)3$78,055N/AN/ACONDUCT STUDY TO ESTABLISH A NATIONAL NORMATIVE NEUROIMAGING LIBRARY
UNIVERSITY OF CHICAGO
6054 SOUTH DREXEL AVECHICAGOIL60637362177139501(C)3$635,748N/AN/APROVIDE SERVICES AND SUPPORT FOR BRAIN COMMONS (DATA-REPOSITORY)
THE BROAD INSTITUTE OF MIT AND HARVARD
415 MAIN STREETCAMBRIDGEMA02142263428781501(C)3$220,784N/AN/APTSD RESEARCH PROGRAMS
UNIVERSITY OF CALIFORNIA SAN DIEGO
9500 GILMAN DRIVELA JOLLACA92093956006144501(C)3$40,090N/AN/AANALYSIS OF GENETIC DATA (GWAS) IN PTSD PATIENTS
OPEN COMMONS CONSORTIUM
400 LATHROP AVENUE SUITE 90RIVER FORESTIL60305261866627501(C)3$143,811N/AN/ABRAIN COMMONS DEVELOPMENT AND MAINTENANCE
MCLEAN HOSPITAL
115 MILL STREETBELMONTMA02142042697981501(C)3N/AREPURPOSED GRANT FUNDSREPURPOSED GRANT FUNDS-$195,094
FieldValueIRS element (for citing)
Total501c3 Org7Total501c3OrgCnt
Total Other Org0TotalOtherOrgCnt

Supplemental Information Detail SupplementalInformationDetail

FieldValueIRS element (for citing)
Form And Line ReferencePART I, LINE 2:FormAndLineReferenceDesc
ExplanationTHE ORGANIZATION REQUIRES GRANTEES TO REGULARLY PROVIDE QUALITATIVE AND QUANTITATIVE REPORTS DESCRIBING HOW FUNDS ARE BEING SPENT AND THE RESULTS THE GRANTEE HAS ACHIEVED. PROGRESS IS MEASURED AGAINST ORIGINAL AND REVISED GRANT PROPOSALS. CONTINUATION OF FUNDING IS DEPENDENT ON RESULTS AND ACCURATE, TIMELY REPORTING.ExplanationTxt

Schedule J IRS990ScheduleJ

FieldValueIRS element (for citing)
Form990 Of Other OrganizationsYes (X)Form990OfOtherOrganizationsInd
Compensation SurveyYes (X)CompensationSurveyInd
Board Or Committee ApprovalYes (X)BoardOrCommitteeApprovalInd
Severance Payment0SeverancePaymentInd
Supplemental Nonqual Rtr Plan0SupplementalNonqualRtrPlanInd
Equity Based Comp Arrngm0EquityBasedCompArrngmInd
Comp Based On Revenue Of Flng Org0CompBasedOnRevenueOfFlngOrgInd
Comp Bsd On Rev Related Orgs0CompBsdOnRevRelatedOrgsInd
Comp Bsd Net Earns Flng Org0CompBsdNetEarnsFlngOrgInd
Comp Bsd Net Earns Rltd Orgs0CompBsdNetEarnsRltdOrgsInd
Any Non Fixed Payments0AnyNonFixedPaymentsInd
Initial Contract Exception0InitialContractExceptionInd

Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (8 entries)

TitleTitleTxtBase Compensation Filing OrgBaseCompensationFilingOrgAmtCompensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmtBonus Filing OrganizationBonusFilingOrganizationAmountBonus Related OrganizationsBonusRelatedOrganizationsAmtOther Compensation Filing OrgOtherCompensationFilingOrgAmtOther Compensation Rltd OrgsOtherCompensationRltdOrgsAmtDeferred Compensation Flng OrgDeferredCompensationFlngOrgAmtDeferred Comp Rltd OrgsDeferredCompRltdOrgsAmtNontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmtNontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmtTotal Compensation Filing OrgTotalCompensationFilingOrgAmtTotal Compensation Rltd OrgsTotalCompensationRltdOrgsAmtComp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmtComp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt
MAGALI HAAS MD PHD
CEO & PRESIDENT$454,184$0$181,692$0$0$0$18,315$0$0$0$654,191$0$0$0
DAVID BIONDI
BOARD MBR/FORMER EXECUTIVE DIR.,CLIN$260,031$0$50,350$0$0$0$15,334$0$13,003$0$338,718$0$0$0
ANDREAS JEROMIN PHD
CHIEF SCIENTIFIC OFFICER$325,470$0$141,728$0$0$0$0$0$15,766$0$482,964$0$0$0
ALLYSON GAGE PHD
CHIEF MEDICAL OFFICER$358,257$0$144,200$0$0$0$16,822$0$7,078$0$526,357$0$0$0
DANIELA BRUNNER PHD
FORMER EXEC. DIR. OF DIGITAL HEALTH$268,264$0$49,029$0$0$0$10,182$0$0$0$327,475$0$0$0
LINDA DYSON
FORMER EXECUTIVE DIRECTOR, PUBLIC AF$191,178$0$0$0$0$0$3,462$0$1,515$0$196,155$0$0$0
AMANDA NICOLE HARMON
EXECUTIVE DIRECTOR, EXTERNAL AFFAIRS$189,253$0$42,667$0$0$0$15,561$0$16,846$0$264,327$0$0$0
FRISO POSTMA
FORMER SENIOR DIRECTOR, EARLY SIGNAL$201,304$0$1,000$0$0$0$12,747$0$0$0$215,051$0$0$0

Schedule L IRS990ScheduleL

Bus Tr Involve Interested Prsn BusTrInvolveInterestedPrsnGrp

Name Of Interested NameOfInterested

Business Name BusinessName

FieldValueIRS element (for citing)
Business Name Line1FRANGIOSA & ASSOCIATESBusinessNameLine1Txt
FieldValueIRS element (for citing)
Relationship DescriptionOWNER IS AN OFFICER OF THE ORGANIZATIONRelationshipDescriptionTxt
Transaction$46,350TransactionAmt
TransactionPROVIDED DISCOUNTED PHARMACEUTICAL MARKET, COMMERCIALIZATION LANDSCAPING AND STRATEGIC CONSULTING SERVICES TO ORGANIZATION.TransactionDesc
Sharing Of Revenues0SharingOfRevenuesInd

Schedule O IRS990ScheduleO

Supplemental Information Detail SupplementalInformationDetail (6 entries)

Form And Line ReferenceFormAndLineReferenceDescExplanationExplanationTxt
FORM 990, PART VI, SECTION B, LINE 11BTHE BOARD OF DIRECTORS REVIEWED AND APPROVED THE FORM 990 PRIOR TO ITS FILING. THE FORM 990 WAS THEN AUTHORIZED AND SIGNED BY THE ORGANIZATION'S CEO & PRESIDENT.
FORM 990, PART VI, SECTION B, LINE 12CTHE BOARD OF DIRECTORS REQUIRES AN ANNUAL DECLARATION FROM ALL BOARD MEMBERS AND SENIOR MANAGEMENT AS TO THE EXISTENCE AND DISCLOSURE OF ANY POTENTIAL CONFLICTS OF INTEREST. THE BOARD MEMBERS SIGN A DISCLOSURE STATEMENT. ANY POTENTIAL CONFLICTS ARE DISCUSSED BY THE DIS-INTERESTED BOARD MEMBERS, WHILE THE PARTY IN POTENTIAL CONFLICT IS REQUIRED TO LEAVE THE ROOM. BOARD MEETING MINUTES WILL DOCUMENT THE DISCUSSION AND DECISION MAKING PROCESS. IN THE EVENT OF A POTENTIAL CONFLICT, PROCEDURES TO OBTAIN COMPETITIVE BIDS AND DILIGENCE ON FAIR MARKET VALUE WILL BE ESTABLISHED.
FORM 990, PART VI, SECTION B, LINE 15CVB'S EXECUTIVE COMPENSATION PROGRAM IS ADMINISTERED BY THE BOARD OF DIRECTORS. THE BOARD IS RESPONSIBLE FOR ESTABLISHING AND MAINTAINING A COMPETITIVE COMPENSATION PROGRAM FOR THE KEY EXECUTIVES OF THE ORGANIZATION. THE BOARD MEETS AS NEEDED TO REVIEW THE COMPENSATION PROGRAM AND MAKE RECOMMENDATIONS FOR ANY CHANGES, AS APPROPRIATE. A PERFORMANCE EVALUATION IS CONDUCTED AND REVIEWED EACH YEAR AND IS INTENDED TO ENSURE THAT THE COMPENSATION PROGRAM FALLS WITHIN A REASONABLE RANGE OF COMPETITIVE PRACTICES FOR COMPARABLE POSITIONS AMONG SIMILARLY SITUATED ORGANIZATIONS. FOLLOWING THIS REVIEW, THE BOARD REVIEWS AND APPROVES, FOR SELECTED KEY EXECUTIVES, BASE SALARIES AND ANNUAL INCENTIVE OPPORTUNITY ADJUSTMENTS, AND OBJECTIVES AND GOALS UPCOMING YEAR'S ANNUAL INCENTIVE PLAN. THE BOARD REVIEWS AND RECOMMENDS TO THE BOARD SALARY APPROVAL AND INCENTIVE AWARDS FOR THE CEO/PRESIDENT AND SELECTED KEY SENIOR STAFF.
FORM 990, PART VI, SECTION C, LINE 19UPON REQUEST AND FORMS AVAILABLE THROUGH CHARITY NAVIGATOR WEBSITE AS WELL.
FORM 990, PART IX, LINE 11GRESEARCH COLLABORATION EXPENSES: PROGRAM SERVICE EXPENSES 2,783,143. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 2,783,143. CONTRACTED SERVICES: PROGRAM SERVICE EXPENSES 3,730,994. MANAGEMENT AND GENERAL EXPENSES 132,754. FUNDRAISING EXPENSES 18,014. TOTAL EXPENSES 3,881,762.
FORM 990, PART XI, LINE 9:CANCELLATION OF GRANT OBLIGATION 924,603.

Schedule R IRS990ScheduleR

Id Disregarded Entities IdDisregardedEntitiesGrp

Disregarded Entity Name DisregardedEntityName

FieldValueIRS element (for citing)
Business Name Line1EARLY SIGNAL LLCBusinessNameLine1Txt

US Address USAddress

FieldValueIRS element (for citing)
Address Line11 BROADWAY 14TH FLOORAddressLine1Txt
CityCAMBRIDGECityNm
State AbbreviationMAStateAbbreviationCd
ZIP02142ZIPCd
FieldValueIRS element (for citing)
Primary ActivitiesTO HOLD INTELLECTUAL PROPERTYPrimaryActivitiesTxt
Legal Domicile StateMALegalDomicileStateCd
Total Income$0TotalIncomeAmt
End Of Year Assets$0EndOfYearAssetsAmt

Direct Controlling Entity Name DirectControllingEntityName

FieldValueIRS element (for citing)
Business Name Line1COHEN VETERANS BIOSCIENCE INCBusinessNameLine1Txt

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.